var data={"title":"Clinical use of neuromuscular blocking agents in anesthesia","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Clinical use of neuromuscular blocking agents in anesthesia</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/contributors\" class=\"contributor contributor_credentials\">Johnathan Ross Renew, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/contributors\" class=\"contributor contributor_credentials\">Mohamed Naguib, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/contributors\" class=\"contributor contributor_credentials\">Sorin J Brull, MD, FCARCSI (Hon)</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/contributors\" class=\"contributor contributor_credentials\">Girish P Joshi, MB, BS, MD, FFARCSI</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/contributors\" class=\"contributor contributor_credentials\">Marianna Crowley, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 28, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H3496590383\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neuromuscular blocking agents (NMBAs) are usually administered during anesthesia to facilitate endotracheal intubation <span class=\"nowrap\">and/or</span> to improve surgical conditions. NMBAs may decrease the incidence of hoarseness and vocal cord injuries during intubation, and can facilitate mechanical ventilation in patients with poor lung compliance [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/1-5\" class=\"abstract_t\">1-5</a>]. </p><p>This topic will discuss the clinical use and pharmacology of the commonly used NMBAs and reversal of neuromuscular block. Monitoring neuromuscular blockade is discussed separately. (See <a href=\"topic.htm?path=monitoring-neuromuscular-blockade\" class=\"medical medical_review\">&quot;Monitoring neuromuscular blockade&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H679390746\"><span class=\"h1\">SELECTION OF NEUROMUSCULAR BLOCKING AGENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The selection of the appropriate neuromuscular blocking agent (NMBA) depends on the clinical application and patient factors. For patients without contraindications to <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a> (eg, hyperkalemia, burns, stroke, susceptibility to malignant hyperthermia), options include the following (see <a href=\"#H996697223\" class=\"local\">'Adverse effects of succinylcholine'</a> below):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For endotracheal intubation for short procedures (&lt;30 minutes), or if neuromonitoring will be used soon after intubation, a short duration of neuromuscular block is required. Options for endotracheal intubation include <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a>, intubation without an NMBA (eg, high dose <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a> intubation, although this technique is associated with more trauma), or <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a> or <a href=\"topic.htm?path=vecuronium-drug-information\" class=\"drug drug_general\">vecuronium</a> if <a href=\"topic.htm?path=sugammadex-drug-information\" class=\"drug drug_general\">sugammadex</a> is available for rapid reversal of block. (See <a href=\"#H3132576103\" class=\"local\">'Sugammadex'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For endotracheal intubation for longer procedures (&ge;30 minutes), <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a> or any of the short or intermediate acting nondepolarizing NMBAs can be used for endotracheal intubation (<a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a>, <a href=\"topic.htm?path=vecuronium-drug-information\" class=\"drug drug_general\">vecuronium</a>, <a href=\"topic.htm?path=mivacurium-drug-information\" class=\"drug drug_general\">mivacurium</a>, <a href=\"topic.htm?path=atracurium-drug-information\" class=\"drug drug_general\">atracurium</a>, or <a href=\"topic.htm?path=cisatracurium-drug-information\" class=\"drug drug_general\">cisatracurium</a>). The choice among these agents depends on availability, cost, and patient factors that affect metabolism. <a href=\"topic.htm?path=pancuronium-drug-information\" class=\"drug drug_general\">Pancuronium</a> is a rarely used, long acting alternative and should be avoided. (See <a href=\"#H3507460328\" class=\"local\">'Nondepolarizing neuromuscular blocking agents'</a> below.) </p><p/><p class=\"bulletIndent1\">Intraoperative relaxation can be maintained as necessary with additional doses of nondepolarizing NMBA. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine</a> provides the most reliable and fastest intubating conditions, and is therefore the preferred NMBA for rapid sequence induction and intubation (RSII). Alternatives to succinylcholine for RSII include high dose <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a> (1.2 <span class=\"nowrap\">mg/kg</span> which is a 4 X ED95 dose), or avoidance of NMBAs with a high dose <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a> intubation. (See <a href=\"topic.htm?path=rapid-sequence-induction-and-intubation-rsii-for-anesthesia#H1078269091\" class=\"medical medical_review\">&quot;Rapid sequence induction and intubation (RSII) for anesthesia&quot;, section on 'Neuromuscular blocking agents (NMBAs)'</a>.) </p><p/><p class=\"headingAnchor\" id=\"H2359769701\"><span class=\"h1\">FACTORS THAT AFFECT THE RESPONSE TO NEUROMUSCULAR BLOCKING AGENTS</span></p><p class=\"headingAnchor\" id=\"H1330254603\"><span class=\"h2\">Patient factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of patient factors can affect the response to neuromuscular blocking agents (NMBAs) or require modification of the dose or interval of administration. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Neuromuscular disease &mdash; </strong>NMBAs should be avoided or doses should be modified in patients with some neuromuscular diseases (<a href=\"image.htm?imageKey=ANEST%2F114209\" class=\"graphic graphic_table graphicRef114209 \">table 1</a>). </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine</a> may cause life threatening hyperkalemia, and should be avoided, in conditions associated with denervation and associated upregulation of nicotinic acetylcholine receptors (nAChRs). (See <a href=\"#H996697223\" class=\"local\">'Adverse effects of succinylcholine'</a> below.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Sensitivity to nondepolarizing NMBAs may be increased or variable in patients with neuromuscular diseases, and administration should be titrated, using careful monitoring. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Patients with myasthenia gravis are resistant to <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a>, but extremely sensitive to nondepolarizing NMBAs. The use of NMBAs in patients with myasthenia gravis is discussed separately. (See <a href=\"topic.htm?path=anesthesia-for-the-patient-with-myasthenia-gravis#H697570641\" class=\"medical medical_review\">&quot;Anesthesia for the patient with myasthenia gravis&quot;, section on 'Neuromuscular blocking agents (NMBAs)'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine</a> is contraindicated in patients with neuromuscular diseases associated with susceptibility to malignant hyperthermia (<a href=\"image.htm?imageKey=SURG%2F65645\" class=\"graphic graphic_table graphicRef65645 \">table 2</a>). (See <a href=\"#H996697223\" class=\"local\">'Adverse effects of succinylcholine'</a> below and <a href=\"topic.htm?path=susceptibility-to-malignant-hyperthermia-evaluation-and-management\" class=\"medical medical_review\">&quot;Susceptibility to malignant hyperthermia: Evaluation and management&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Burns &mdash; </strong>Burn injury upregulates extrajunctional nAChRs beginning within 24 hours of injury. As a result, administration of <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a> after 48 hours, and for up to a year after a major burn, can cause severe hyperkalemia and life threatening arrhythmias, and should be avoided. Upregulation of nAChRs also causes resistance to nondepolarizing NMBAs and reduces duration of action. (See <a href=\"topic.htm?path=anesthesia-for-burn-patients#H262189525\" class=\"medical medical_review\">&quot;Anesthesia for burn patients&quot;, section on 'Neuromuscular blocking agents'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Extremes of age &mdash;</strong> In elderly patients, the effects of steroidal NMBAs are prolonged due to decreased volume of distribution, changes in circulatory physiology, decreased regional renal and hepatic blood flow, and anatomic changes at the neuromuscular junction (NMJ). As such, smaller doses and less frequent dosing intervals may be warranted. The use of objective monitoring is particularly useful in this patient population (<a href=\"image.htm?imageKey=ANEST%2F114210\" class=\"graphic graphic_table graphicRef114210 \">table 3</a> and <a href=\"image.htm?imageKey=ANEST%2F114207\" class=\"graphic graphic_table graphicRef114207 \">table 4</a>).</p><p/><p class=\"bulletIndent1\">Administration of NMBAs in infants and children is discussed separately. (See <a href=\"topic.htm?path=general-anesthesia-in-neonates-and-children-agents-and-techniques#H75956366\" class=\"medical medical_review\">&quot;General anesthesia in neonates and children: Agents and techniques&quot;, section on 'Neuromuscular blocking agents'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Obesity &mdash; </strong>The dose of <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a> should be based on total body weight for optimal intubating conditions [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/6\" class=\"abstract_t\">6</a>]. Studies of the effects of obesity on the pharmacodynamics of various nondepolarizing NMBAs are conflicting, and the optimal method for calculating doses in very obese patients is unclear [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/7,8\" class=\"abstract_t\">7,8</a>]. We calculate doses for nondepolarizing NMBAs based on ideal body weight plus 10 percent, and use objective neuromuscular monitoring to minimize the risk of prolonged paralysis [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/9\" class=\"abstract_t\">9</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hepatic and renal disease &mdash; </strong>Benzylisoquinolinium NMBAs are preferred for patients with hepatic or renal dysfunction, since clearance of these drugs is independent of organ function. The duration of action of the steroidal NMBAs may be prolonged in these patients because of decreased clearance (<a href=\"image.htm?imageKey=ANEST%2F114271\" class=\"graphic graphic_table graphicRef114271 \">table 5</a>). </p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine</a> may be used for patients with renal disease, as long as serum potassium is normal. In these patients, the transient rise in potassium associated with succinylcholine is similar to patients without renal disease [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/10\" class=\"abstract_t\">10</a>]. (See <a href=\"#H996697223\" class=\"local\">'Adverse effects of succinylcholine'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Physiologic derangements </strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Hypothermia &mdash; </strong>Hypothermia causes a prolonged response to nondepolarizing NMBAs as lower temperatures can affect excretion, volume of distribution, interactions with postjunctional nAChRs, and the pH at the NMJ [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/11,12\" class=\"abstract_t\">11,12</a>]. This response is proportional to the degree of hypothermia but becomes more pronounced when muscle temperature is lower than 35.2&deg;C [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/13\" class=\"abstract_t\">13</a>]. It is important to note that neuromuscular monitoring is still reliable in this setting and can help guide neuromuscular blockade management in the hypothermic patient. &#160;</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Electrolyte disturbances </strong></p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Hypermagnesemia causes muscle relaxation, potentiates the effects of NMBAs, and can prolong the duration of action of <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a>, <a href=\"topic.htm?path=cisatracurium-drug-information\" class=\"drug drug_general\">cisatracurium</a>, and <a href=\"topic.htm?path=vecuronium-drug-information\" class=\"drug drug_general\">vecuronium</a>. Hypermagnesemia is usually iatrogenic. As an example, magnesium is routinely administered in the intrapartum and postpartum period for patients with preeclampsia to prevent seizures. If these patients require general anesthesia, nondepolarizing NMBAs are rarely necessary and should be avoided. Since magnesium does not potentiate the effects of <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a>, usual rapid sequence induction and intubation doses (succinylcholine 1 to 1.5 <span class=\"nowrap\">mg/kg</span> IV) should be administered. (See <a href=\"topic.htm?path=anesthesia-for-the-patient-with-preeclampsia#H3140834780\" class=\"medical medical_review\">&quot;Anesthesia for the patient with preeclampsia&quot;, section on 'Intraoperative magnesium'</a>.)</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Hypercalcemia causes a reduced response to the administration of nondepolarizing NMBAs as calcium triggers the release of acetylcholine into the NMJ and enhances the excitation-contraction coupling of the myocytes [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/14\" class=\"abstract_t\">14</a>]. Thus, hypercalcemic patients may require larger doses of nondepolarizing NMBA to achieve the desired level of neuromuscular blockade.</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Hypocalcemia should be confirmed by measuring ionized calcium, and excluding falsely low levels of calcium due to low plasma albumin levels. Plasma calcium can have antagonistic actions at the neuromuscular junction; at the presynaptic membrane, it can decrease the amplitude of depolarization, thus antagonizing nondepolarizing block [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/15\" class=\"abstract_t\">15</a>]. At the postsynaptic membrane, calcium decreases the degree of depolarization produced by acetylcholine, thus potentiating nondepolarizing block [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/16\" class=\"abstract_t\">16</a>]. For these reasons, the overall effect of calcium on neuromuscular transmission is unpredictable [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/14\" class=\"abstract_t\">14</a>]. </p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Hypokalemia may antagonize the duration of nondepolarizing agents, but has no effect on the duration of depolarizing block [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/17\" class=\"abstract_t\">17</a>]. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Acidosis &mdash; </strong>Acidosis, whether metabolic or respiratory in origin, can prolong the effects of NMBAs, by increasing NMBA affinity for postjunctional nACHRs. Acidosis also causes a relative hypocalcemia, which can prolong neuromuscular block [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/15,18\" class=\"abstract_t\">15,18</a>]. Conversely, alkalosis can shorten the duration of neuromuscular blockade produced by nondepolarizing muscle relaxants, but will not affect the duration of action of depolarizing muscle relaxants [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/17\" class=\"abstract_t\">17</a>]. These perturbations can occur once pH becomes lower than 7.3 or greater than 7.51 [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/18\" class=\"abstract_t\">18</a>].</p><p/><p class=\"headingAnchor\" id=\"H2313054767\"><span class=\"h2\">Drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of drugs can either enhance or inhibit the response to NMBAs, and may require modification of the dose or interval of administration, guided by monitoring.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Combinations of NMBAs &mdash; </strong>In some clinical circumstances,<strong> </strong><a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a> may be administered before or after a nondepolarizing NMBA, or two different nondepolarizing NMBAs may be administered in sequence. Combinations of NMBAs can affect the resulting degree of neuromuscular block, and subsequent management should be guided by the use of a neuromuscular function monitor. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Prior administration of any nondepolarizing neuromuscular blocking drug has a substantial antagonistic effect on the subsequent depolarizing block induced by <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a>. As an example, if a defasciculating dose of a nondepolarizing NMBA is administered prior to succinylcholine, the dose of succinylcholine must be increased [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/19\" class=\"abstract_t\">19</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In contrast, the effect of prior administration of <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a> on subsequent administration of a nondepolarizing neuromuscular block depends on the drug used. Studies have reported that administration of succinylcholine prior to a nondepolarizing NMBA does not affect the potency of <a href=\"topic.htm?path=mivacurium-drug-information\" class=\"drug drug_general\">mivacurium</a> [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/20\" class=\"abstract_t\">20</a>] or <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a> [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/21\" class=\"abstract_t\">21</a>], but speeds the onset, increases the potency, and prolongs the duration of action of <a href=\"topic.htm?path=vecuronium-drug-information\" class=\"drug drug_general\">vecuronium</a> and <a href=\"topic.htm?path=cisatracurium-drug-information\" class=\"drug drug_general\">cisatracurium</a> [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/22\" class=\"abstract_t\">22</a>]. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Combining two nondepolarizing NMBAs of the same structural class, such as <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a> and <a href=\"topic.htm?path=vecuronium-drug-information\" class=\"drug drug_general\">vecuronium</a>, produces an additive interaction [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/23\" class=\"abstract_t\">23</a>]. Combining two nondepolarizing NMBAs from different structural classes, such as rocuronium and <a href=\"topic.htm?path=cisatracurium-drug-information\" class=\"drug drug_general\">cisatracurium</a>, results in a synergistic response [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/24\" class=\"abstract_t\">24</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Inhaled anesthetics &mdash; </strong>Inhaled anesthetics inhibit nAChRs and potentiate neuromuscular blockade with nondepolarizing NMBAs [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/25\" class=\"abstract_t\">25</a>]. This potentiation depends on the type of volatile anesthetic (<a href=\"topic.htm?path=desflurane-drug-information\" class=\"drug drug_general\">desflurane</a> &gt; <a href=\"topic.htm?path=sevoflurane-drug-information\" class=\"drug drug_general\">sevoflurane</a> &gt; <a href=\"topic.htm?path=isoflurane-drug-information\" class=\"drug drug_general\">isoflurane</a> &gt; <a href=\"topic.htm?path=nitrous-oxide-drug-information\" class=\"drug drug_general\">nitrous oxide</a>), the concentration, and the duration of exposure [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/26-28\" class=\"abstract_t\">26-28</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Antibiotics</strong> &mdash; Tetracyclines, aminoglycosides, polymyxins, and <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a> potentiate neuromuscular blockade through inhibition of acetylcholine (ACh) release or desensitization of postjunctional nAChRs to ACh [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/29\" class=\"abstract_t\">29</a>]. In practice, this interaction is most relevant during maintenance of anesthesia. Antibiotics typically are given after a dose of NMBA has already been administered for induction of anesthesia. Thus the interaction between such antibiotics and nondepolarizing NMBAs must be considered when re-dosing NMBAs. Appropriate (objective) monitoring is particularly helpful in this setting. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Antiseizure drugs &ndash;</strong> Patients receiving chronic treatment are relatively resistant to nondepolarizing NMBAs due to accelerated clearance of these drugs [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/30,31\" class=\"abstract_t\">30,31</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">Lithium</a><strong> &mdash; </strong>Patients who take lithium can have a prolonged response to both depolarizing and nondepolarizing NMBAs [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/32\" class=\"abstract_t\">32</a>]. Lithium structurally resembles other cations, such as sodium, potassium, magnesium, and calcium. This resemblance to such cations activates potassium channels, inhibiting neuromuscular transmission. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Antidepressants &mdash; </strong>In laboratory studies, <a href=\"topic.htm?path=sertraline-drug-information\" class=\"drug drug_general\">sertraline</a> and <a href=\"topic.htm?path=amitriptyline-drug-information\" class=\"drug drug_general\">amitriptyline</a> inhibit butyrylcholinesterase [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/33\" class=\"abstract_t\">33</a>], and prolonged paralysis after administration of <a href=\"topic.htm?path=mivacurium-drug-information\" class=\"drug drug_general\">mivacurium</a> has been reported in a patient who was chronically taking sertraline [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/34\" class=\"abstract_t\">34</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Local anesthetics &mdash;</strong> Local anesthetics (LAs) may enhance the effects of both depolarizing and nondepolarizing NMBAs through pre- and post-synaptic interactions at the neuromuscular junction (NMJ) [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/35,36\" class=\"abstract_t\">35,36</a>]. Administration of LAs for regional anesthesia may result in blood levels high enough to potentiate NMBA induced neuromuscular block. Epidurally administered levobupivacaine [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/37\" class=\"abstract_t\">37</a>] and <a href=\"topic.htm?path=mepivacaine-drug-information\" class=\"drug drug_general\">mepivacaine</a> [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/38\" class=\"abstract_t\">38</a>] potentiate amino-steroidal NMBAs and delay recovery from neuromuscular blockade.</p><p/><p class=\"bulletIndent1\">Data on the effects of <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> on neuromuscular block are conflicting. Whereas one study reported that epidural lidocaine potentiated <a href=\"topic.htm?path=vecuronium-drug-information\" class=\"drug drug_general\">vecuronium</a> induced neuromuscular block [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/39\" class=\"abstract_t\">39</a>], several studies have reported no effect of intravenous lidocaine on the onset, duration, or recovery from <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a> induced neuromuscular block [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/40-42\" class=\"abstract_t\">40-42</a>].</p><p/><p class=\"headingAnchor\" id=\"H115343747\"><span class=\"h1\">CLINICAL USE OF NEUROMUSCULAR BLOCKING AGENTS</span></p><p class=\"headingAnchor\" id=\"H2476711246\"><span class=\"h2\">Endotracheal intubation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most common indication for the use of neuromuscular blocking agents (NMBAs) in anesthesia is to facilitate endotracheal intubation. The goal of muscle paralysis for endotracheal intubation is to achieve ideal intubation conditions, which are dependent on the depth of anesthesia, airway anatomy, and the experience of the anesthesiologist, in addition to the depth of neuromuscular block (<a href=\"image.htm?imageKey=ANEST%2F114082\" class=\"graphic graphic_table graphicRef114082 \">table 6</a>). More intense block is associated with better intubation conditions; a dose of 2 X ED95 for a given NMBA should be sufficient for routine intubation [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/43,44\" class=\"abstract_t\">43,44</a>]. </p><p>The use of NMBAs may reduce the incidence of postintubation hoarseness and airway injury [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/5,45\" class=\"abstract_t\">5,45</a>]. A 2017 meta-analysis of randomized controlled trials that compared endotracheal intubation with NMBAs and without NMBAs reported increased risks of difficult intubation and an increased risk of upper airway discomfort and injury if NMBAs were avoided for intubation, but the overall quality of the evidence was moderate to low [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/46\" class=\"abstract_t\">46</a>].</p><p><a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine</a> is commonly used for endotracheal intubation because of its reliable and rapid onset of neuromuscular blockade. Skeletal muscle relaxation can be assumed immediately after resolution of the fasciculations that occur with succinylcholine. (See <a href=\"#H996697223\" class=\"local\">'Adverse effects of succinylcholine'</a> below.) After administration of succinylcholine, a nondepolarizing NMBA should not be administered until return of neuromuscular function has been documented, as confirmation of normal pseudocholinesterase activity. (See <a href=\"#H2104230870\" class=\"local\">'Butyrylcholinesterase (pseudocholinesterase) deficiency'</a> below.)</p><p>Nondepolarizing NMBAs do not cause fasciculations. Therefore, we suggest the use of an objective neuromuscular function monitor to determine when optimal neuromuscular blockade is achieved after administration of nondepolarizing NMBAs for endotracheal intubation. Central muscle groups (eg, the diaphragm and laryngeal adductors) are blocked faster than peripheral muscle groups (eg, adductor pollicis) after the administration of NMBA [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/47\" class=\"abstract_t\">47</a>]. Therefore, if optimal neuromuscular blockade (defined as total suppression of evoked responses to train-of-four [TOF] stimulation) is confirmed by monitoring adductor pollicis stimulation, pharyngeal muscles are usually blocked as well, and optimal intubating conditions are achieved. </p><p>The onset time of nondepolarizing NMBAs can be shortened by increasing the dose. As an example, <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a> can be used for rapid sequence induction and intubation within 60 seconds by administration of twice the usual intubation dose (or four times the ED<sub>95</sub>). (See <a href=\"#H874124449\" class=\"local\">'Rocuronium'</a> below and <a href=\"topic.htm?path=rapid-sequence-induction-and-intubation-rsii-for-anesthesia#H714699616\" class=\"medical medical_review\">&quot;Rapid sequence induction and intubation (RSII) for anesthesia&quot;, section on 'Nondepolarizing NMBAs'</a>.) </p><p>Rapid onset of paralysis can also be achieved by administration of a priming dose (10 percent of the intubating dose) several minutes prior to the intubating dose [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/48\" class=\"abstract_t\">48</a>]. Since the priming dose of NMBA may cause signs of paralysis, including diplopia, blurry vision, difficulty swallowing, and risk of aspiration, we do not routinely administer a priming dose of NMBA [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/49\" class=\"abstract_t\">49</a>].</p><p class=\"headingAnchor\" id=\"H1994682241\"><span class=\"h2\">Facilitation of surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nondepolarizing NMBAs may be used to provide muscle relaxation that improves surgical conditions. However, many operations can be performed without the need to use any NMBAs, and administration of NMBAs should be individualized [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/50,51\" class=\"abstract_t\">50,51</a>]. Neuromuscular blockade may improve surgical conditions during laparoscopic, robotic, abdominal, and thoracic procedures, by reducing patient movement, muscle tone, and breathing or coughing against the ventilator [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/2,52-54\" class=\"abstract_t\">2,52-54</a>]. NMBAs also allow lower insufflation pressures during laparoscopy, but the relationship between insufflation pressure and surgical exposure is unclear. The benefits of deep versus moderate muscle relaxation during laparoscopy are also unclear [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/55-57\" class=\"abstract_t\">55-57</a>]. Many of the theoretical benefits of neuromuscular blockade can be achieved by making sure that patients are adequately anesthetized at all times during surgery (<a href=\"image.htm?imageKey=ANEST%2F114082\" class=\"graphic graphic_table graphicRef114082 \">table 6</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Moderate neuromuscular block &mdash; </strong>When neuromuscular blockade is indicated, for most surgical procedures we aim for moderate levels of blockade (ie, two to three twitches using an objective peripheral nerve stimulator (<a href=\"image.htm?imageKey=ANEST%2F114139\" class=\"graphic graphic_figure graphicRef114139 \">figure 1</a>)). (See <a href=\"topic.htm?path=monitoring-neuromuscular-blockade#H1932544448\" class=\"medical medical_review\">&quot;Monitoring neuromuscular blockade&quot;, section on 'Train-of-four'</a>.) &#160;</p><p/><p class=\"bulletIndent1\">Once neuromuscular block begins to recover from the deep level of paralysis required for endotracheal intubation, a moderate level of block may be maintained with interval dosing or an infusion of nondepolarizing NMBA, guided by monitoring. When guided by objective monitoring, administration of NMBAs by infusion may reduce the total dose required for surgical relaxation [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/58\" class=\"abstract_t\">58</a>]. </p><p/><p class=\"bulletIndent1\">At the conclusion of abdominal surgery, a moderate level of relaxation of abdominal muscles is often sufficient to facilitate closure of the wound. A deep level of block should be avoided at this stage of the operation to allow rapid and complete reversal of the NMBA. If necessary, the anesthetic can be deepened temporarily (ie, with inhalation agent or <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>) to facilitate closure without administration of NMBA.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Deep neuromuscular blockade &mdash; </strong>Deep levels of neuromuscular blockade (zero to one twitch) may be warranted in specific settings, in addition to ensuring adequate depth of anesthesia. As an example, complete paralysis may be indicated during delicate dissection under the microscope during craniotomy, when any unexpected movement must be avoided. (See <a href=\"topic.htm?path=anesthesia-for-intracranial-neurovascular-procedures-in-adults#H2047322396\" class=\"medical medical_review\">&quot;Anesthesia for intracranial neurovascular procedures in adults&quot;, section on 'Patient immobility'</a>.) </p><p/><p/><p class=\"headingAnchor\" id=\"H1726332908\"><span class=\"h1\">AVOIDANCE OF RESIDUAL NEUROMUSCULAR BLOCKADE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>One primary goal for anesthetic management is to ensure complete recovery of neuromuscular function at the end of anesthesia (ie, train-of-four ratio [TOFR] &ge;0.9). Residual neuromuscular block after administration of neuromuscular blocking agents (NMBAs) is an important risk factor for anesthesia related morbidity and mortality. Even minor degrees of residual block are associated with weakness of upper airway muscles, airway obstruction, increased risk of aspiration, and unpleasant muscle weakness. Incomplete postoperative neuromuscular recovery can also cause prolonged recovery room stay, hypoxemia and airway obstruction, awareness during emergence from anesthesia, and increased postoperative pulmonary complications [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/59-61\" class=\"abstract_t\">59-61</a>].</p><p>Multiple studies have reported that residual neuromuscular block is a common problem. In a meta-analysis of 24 randomized and observational studies including 3375 patients anesthetized between 1979 and 2005, residual block (train-of-four ratio &lt;0.9) occurred in 41 percent of patients who received intermediate acting NMBAs [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/62\" class=\"abstract_t\">62</a>]. </p><p>A suggested strategy for avoidance of residual neuromuscular blockade is as follows: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Use intermediate or short acting NMBAs, rather than long acting NMBAs (eg, <a href=\"topic.htm?path=pancuronium-drug-information\" class=\"drug drug_general\">pancuronium</a>) whenever possible</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Avoid deep neuromuscular blockade (ie, train-of-four count [TOFC] = 0) when clinically appropriate</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Use objective neuromuscular monitoring whenever possible to guide administration of NMBAs and assess recovery of neuromuscular function for all patients who receive NMBAs</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If only a peripheral nerve stimulator is available, ensure electrode placement is not causing direct muscle stimulation (<a href=\"image.htm?imageKey=ANEST%2F114145\" class=\"graphic graphic_figure graphicRef114145 \">figure 2</a> and <a href=\"image.htm?imageKey=ANEST%2F114147\" class=\"graphic graphic_figure graphicRef114147 \">figure 3</a>). </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Avoid monitoring facial muscles as this will overestimate the degree of recovery. If the arms are not accessible due to surgical positioning, monitor the facial muscles but transition to the arms once they become available.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Administer reversal agents in appropriate doses, and guided by the degree of recovery from neuromuscular block (<a href=\"image.htm?imageKey=ANEST%2F114082\" class=\"graphic graphic_table graphicRef114082 \">table 6</a>). (See <a href=\"#H154268994\" class=\"local\">'Reversal of neuromuscular block'</a> below.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Administer no reversal agents if adequate spontaneous recovery has been achieved, as demonstrated by a quantitative TOFR &gt;0.9.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Administer <a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">neostigmine</a>, in appropriate doses, only if spontaneous recovery has reached a TOFC &gt;3.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If spontaneous recovery has not reached a TOFC &gt;3, use <a href=\"topic.htm?path=sugammadex-drug-information\" class=\"drug drug_general\">sugammadex</a> rather than <a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">neostigmine</a> for reversal of steroidal NMBAs. If sugammadex is unavailable (or if using benzylisoquinolinium NMBAs), wait for spontaneous recovery to achieve a TOFC &gt;3 before administering neostigmine. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Extubate the trachea only after a TOFR &ge;0.9 is achieved (when objective monitors are available).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If a quantitative monitor is not available, during <a href=\"topic.htm?path=sevoflurane-drug-information\" class=\"drug drug_general\">sevoflurane</a> anesthesia allow at least 15 minutes after <a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">neostigmine</a> administration before extubation of the trachea if neostigmine is administered at a TOFC of 3, and at least 10 minutes if neostigmine is administered at a TOFC of 4. During intravenous anesthesia with <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, wait at least five minutes after administration of neostigmine to extubate the trachea when neostigmine is administered at a TOFC &ge;3. (See <a href=\"#H1667432385\" class=\"local\">'Anticholinesterases'</a> below.) </p><p/><p class=\"headingAnchor\" id=\"H154268994\"><span class=\"h1\">REVERSAL OF NEUROMUSCULAR BLOCK</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A train-of-four ratio (TOFR) &ge;0.9 should be achieved prior to tracheal extubation following administration of neuromuscular blocking agents (NMBAs) [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/63\" class=\"abstract_t\">63</a>]. Reversal of neuromuscular block after administration of NMBAs can occur by spontaneous recovery, or by administration of reversal agents. Reversal agents include anticholinesterases and <a href=\"topic.htm?path=sugammadex-drug-information\" class=\"drug drug_general\">sugammadex</a>, the only available selective relaxant reversal agent, which is specific for aminosteroid nondepolarizing NMBAs. </p><p>The recommended doses of the commonly used reversal agents and the time course of recovery from various levels of <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a> induced neuromuscular block are shown in a figure and a table (<a href=\"image.htm?imageKey=ANEST%2F114148\" class=\"graphic graphic_figure graphicRef114148 \">figure 4</a> and <a href=\"image.htm?imageKey=ANEST%2F114082\" class=\"graphic graphic_table graphicRef114082 \">table 6</a>). </p><p class=\"headingAnchor\" id=\"H3662862510\"><span class=\"h2\">Spontaneous recovery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reversal agents should only be omitted when clinicians can confirm adequate recovery from neuromuscular blockade to a TOFR of 0.9 or greater using quantitative monitoring. The response to single intubating doses of NMBAs is variable among patients and responses can be difficult to predict. As an example, a large trial found that after a single intubating dose of an intermediate-acting NMBA, 37 percent of patients had not spontaneously recovered to a TOFR of 0.9 two hours after administration [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/64\" class=\"abstract_t\">64</a>].</p><p class=\"headingAnchor\" id=\"H1667432385\"><span class=\"h2\">Anticholinesterases</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Anticholinesterase agents work by increasing the availability of acetylcholine at the neuromuscular junction, to compete with nondepolarizing NMBAs for nicotinic acetylcholine receptors and restore neuromuscular transmission. The anticholinesterases available for reversal of NBMA are <a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">neostigmine</a> and <a href=\"topic.htm?path=edrophonium-drug-information\" class=\"drug drug_general\">edrophonium</a>. Neostigmine is usually preferred, despite a slower onset of action than edrophonium, because neostigmine has higher affinity for acetylcholine receptors. Both drugs have a duration of action of 60 to 120 minutes [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/65\" class=\"abstract_t\">65</a>].</p><p>Blockade of cholinesterase occurs at all cholinergic sites, including muscarinic receptors, such that these drugs have parasympathomimetic effects. Therefore, anticholinergic, antimuscarinic drugs (ie, <a href=\"topic.htm?path=atropine-drug-information\" class=\"drug drug_general\">atropine</a> or <a href=\"topic.htm?path=glycopyrrolate-glycopyrronium-drug-information\" class=\"drug drug_general\">glycopyrrolate</a>) are administered along with anticholinesterases to prevent bradycardia and gastrointestinal side effects. &#160; </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">Neostigmine</a><strong> &mdash; </strong>Neostigmine is the anticholinesterase agent most commonly used for reversal of neuromuscular blockade. <a href=\"topic.htm?path=glycopyrrolate-glycopyrronium-drug-information\" class=\"drug drug_general\">Glycopyrrolate</a> is routinely administered along with neostigmine (0.2 mg glycopyrrolate IV for each 1 mg neostigmine IV) as they have a similar onset of action.</p><p/><p class=\"bulletIndent1\">The rate of reversal of neuromuscular block with <a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">neostigmine</a> is variable. Factors that affect the speed of reversal include the depth of existing block, the dose of neostigmine, and the other factors that can affect the degree of neuromuscular block (eg, inhalation anesthesia, hypothermia, acidosis, electrolyte disturbances, hypercarbia, patient age) [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/66,67\" class=\"abstract_t\">66,67</a>]. (See <a href=\"#H2359769701\" class=\"local\">'Factors that affect the response to neuromuscular blocking agents'</a> above.) </p><p/><p class=\"bulletIndent1\">Reversal of neuromuscular block with <a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">neostigmine</a> takes longer during inhalation anesthesia than during intravenous anesthesia with <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>. In one study, 160 patients were randomly assigned to maintenance of anesthesia with <a href=\"topic.htm?path=sevoflurane-drug-information\" class=\"drug drug_general\">sevoflurane</a> or propofol, and reversal of <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a> with neostigmine at different levels of block. The median time from administration of neostigmine at a train-of-four count (TOFC) of 3 to recovery to a TOFR of 0.9 was 15.6 minutes (7.3 to 43.9) during sevoflurane anesthesia and was 5.4 minutes (1.6 to 8.6) during propofol anesthesia [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/67\" class=\"abstract_t\">67</a>]. The median time to recovery if neostigmine was administered at TOFC of 4 was 9.7 minutes (5.1 to 26.4) during sevoflurane anesthesia, and 4.7 minutes (1.3 to 7.2) during propofol anesthesia.</p><p/><p class=\"bulletIndent1\">If sufficient spontaneous recovery (train-of-four [TOF] &gt;0.90) can be confirmed through quantitative monitoring, <a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">neostigmine</a> is unnecessary. If quantitative monitoring is not available, or this level of recovery has not been achieved, neostigmine (or <a href=\"topic.htm?path=sugammadex-drug-information\" class=\"drug drug_general\">sugammadex</a>) should be administered in an appropriate dose based on the degree of neuromuscular block at the time of administration (<a href=\"image.htm?imageKey=ANEST%2F114148\" class=\"graphic graphic_figure graphicRef114148 \">figure 4</a> and <a href=\"image.htm?imageKey=ANEST%2F114082\" class=\"graphic graphic_table graphicRef114082 \">table 6</a>). </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">Neostigmine</a> is ineffective at reversing deep levels of neuromuscular blockade (post-tetanic count [PTC] &ge;1, train-of-four count [TOFC] = 0) [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/66\" class=\"abstract_t\">66</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">Neostigmine</a> should be administered at doses &lt;60 to 70 <span class=\"nowrap\">mcg/kg</span> IV. Higher doses than these are no more effective, and increase the risk of a direct neuromuscular blocking effect of the drug.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">Neostigmine</a> should be administered at a TOFC of 3 to 4 [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/68\" class=\"abstract_t\">68</a>]. At this level of block, neostigmine doses of 20 to 50 <span class=\"nowrap\">mcg/kg</span> may be sufficient to effect adequate recovery [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/69\" class=\"abstract_t\">69</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The use of <a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">neostigmine</a> in the absence of NMBAs, in excessive doses at shallow levels of neuromuscular block, or in doses that exceed 70 <span class=\"nowrap\">mcg/kg,</span> can result in paradoxical neuromuscular weakness [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/70-72\" class=\"abstract_t\">70-72</a>]. However, administration of a modest dose of neostigmine (ie, &lt;50 <span class=\"nowrap\">mcg/kg</span> IV) during recovery from neuromuscular blockade, even at TOFR &gt;0.9, is unlikely to result in clinically significant weakness. This was demonstrated by a study in which 90 anesthetized patients who had recovered to a TOFR &gt;0.9 after a single dose of <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a> were randomly assigned to receive neostigmine 40 <span class=\"nowrap\">mcg/kg</span> IV or saline [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/73\" class=\"abstract_t\">73</a>]. There were no differences in TOFR five minutes after reversal or on admission to the postanesthesia care unit, and no differences in postoperative weakness, hypoxemia, or airway obstruction. &#160;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=edrophonium-drug-information\" class=\"drug drug_general\">Edrophonium</a><strong> &mdash; </strong>Edrophonium has a faster onset (one to two minutes) than <a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">neostigmine</a> and is usually coadministered with <a href=\"topic.htm?path=atropine-drug-information\" class=\"drug drug_general\">atropine</a> (0.7 to 1.4 <span class=\"nowrap\">mcg/kg),</span> which has a similar onset of action, to block antimuscarinic effects. Binding of edrophonium to acetylcholinesterases is much weaker than the neostigmine, and it should only be used at shallow levels of neuromuscular blockade. The standard dose of 0.5 to 1.0 <span class=\"nowrap\">mg/kg</span> results in a similar duration of antagonism as neostigmine [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/65\" class=\"abstract_t\">65</a>].</p><p/><p class=\"headingAnchor\" id=\"H3132576103\"><span class=\"h2\">Sugammadex</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=sugammadex-drug-information\" class=\"drug drug_general\">Sugammadex</a> is a gamma-cyclodextrin that encapsulates and subsequently inactivates steroidal NMBAs. Affinity is greatest for <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a>, followed in decreasing order of affinity by <a href=\"topic.htm?path=vecuronium-drug-information\" class=\"drug drug_general\">vecuronium</a>, <a href=\"topic.htm?path=pancuronium-drug-information\" class=\"drug drug_general\">pancuronium</a>, and pipecuronium [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/74\" class=\"abstract_t\">74</a>]. Sugammadex has no effect on <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a> or the benzylisoquinolinium NMBAs.</p><p>After administration, binding occurs in plasma, leading to a rapid decrease in the plasma levels of unbound NMBA molecules. This results in a concentration gradient between the free NMBA molecules at the neuromuscular junction (NMJ) and in the plasma, leading to a net transfer of unbound NMBA back into the plasma, where it is encapsulated by unbound <a href=\"topic.htm?path=sugammadex-drug-information\" class=\"drug drug_general\">sugammadex</a>. This rapid decrease in free NMBA at the NMJ results in rapid and effective antagonism and restoration of normal transmission and neuromuscular function. Sugammadex reversal produces a more complete and faster recovery than <a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">neostigmine</a> or <a href=\"topic.htm?path=edrophonium-drug-information\" class=\"drug drug_general\">edrophonium</a> reversal [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/75,76\" class=\"abstract_t\">75,76</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dosing &ndash;</strong> The dose of <a href=\"topic.htm?path=sugammadex-drug-information\" class=\"drug drug_general\">sugammadex</a> should be based on the level of neuromuscular block (<a href=\"image.htm?imageKey=ANEST%2F114148\" class=\"graphic graphic_figure graphicRef114148 \">figure 4</a>). &#160;</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At a deep level of neuromuscular blockade (PTC 1 to 2), a dose of 4 <span class=\"nowrap\">mg/kg</span> results in recovery to a TOFR &ge;0.9 within five minutes [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/77\" class=\"abstract_t\">77</a>]. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At moderate level of neuromuscular block (TOFC 2 to 4), a dose of <a href=\"topic.htm?path=sugammadex-drug-information\" class=\"drug drug_general\">sugammadex</a> of 2 <span class=\"nowrap\">mg/kg</span> IV results in a TOFR &ge; 0.9 in three to four minutes [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/78\" class=\"abstract_t\">78</a>]. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In emergent situations in which intubation and ventilation are unexpectedly difficult or impossible, 16 <span class=\"nowrap\">mg/kg</span> <a href=\"topic.htm?path=sugammadex-drug-information\" class=\"drug drug_general\">sugammadex</a> can reverse profound rocuronium-induced blockade within three minutes [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/79\" class=\"abstract_t\">79</a>]. Whereas rapid reversal of neuromuscular block may be helpful in this setting, a number of other factors may affect the restoration of spontaneous ventilation (eg, coadministered anesthetics and opioids, patient factors). (See <a href=\"topic.htm?path=management-of-the-difficult-airway-for-general-anesthesia-in-adults#H346443\" class=\"medical medical_review\">&quot;Management of the difficult airway for general anesthesia in adults&quot;, section on 'The failed airway'</a>.)</p><p/><p class=\"bulletIndent1\">Administration of excessive doses of <a href=\"topic.htm?path=sugammadex-drug-information\" class=\"drug drug_general\">sugammadex</a> should be avoided, because the incidence of anaphylaxis with sugammadex is proportional to the dose administered [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/80\" class=\"abstract_t\">80</a>], excessive administration may prevent or delay subsequent reestablishment of neuromuscular block with steroidal NMBAs, and sugammadex is expensive.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Elimination</strong> &ndash; The sugammadex-NMBA complex is excreted in the urine unchanged [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/81\" class=\"abstract_t\">81</a>]. While <a href=\"topic.htm?path=sugammadex-drug-information\" class=\"drug drug_general\">sugammadex</a> is not recommended for use in patients with end-stage renal disease, the <span class=\"nowrap\">sugammadex/<a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a></span> complex can be removed by dialysis if necessary [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/82\" class=\"abstract_t\">82</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Drug interactions &ndash;</strong> <a href=\"topic.htm?path=sugammadex-drug-information\" class=\"drug drug_general\">Sugammadex</a> can bind and inhibit oral contraceptives. Patients should use alternative contraceptive techniques for seven days after exposure to sugammadex [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/83\" class=\"abstract_t\">83</a>]. Reestablishing neuromuscular blockade with steroidal NMBA within three hours of sugammadex administration requires increased doses [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/84\" class=\"abstract_t\">84</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Adverse effects &ndash;</strong> Anaphylactic reactions occur in between 1:3500 and 1:20,000 exposures to <a href=\"topic.htm?path=sugammadex-drug-information\" class=\"drug drug_general\">sugammadex</a>, and such events typically occur within the first four minutes of administration [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/85\" class=\"abstract_t\">85</a>]. The incidence of anaphylaxis is proportional to the dose administered [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/80\" class=\"abstract_t\">80</a>]. </p><p/><p class=\"bulletIndent1\">Small increases in coagulation parameters have been reported after <a href=\"topic.htm?path=sugammadex-drug-information\" class=\"drug drug_general\">sugammadex</a> administration, but clinically significant bleeding has not been reported [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/86\" class=\"abstract_t\">86</a>].</p><p/><p class=\"headingAnchor\" id=\"H3484879739\"><span class=\"h1\">CLASSIFICATION OF NEUROMUSCULAR BLOCKING AGENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neuromuscular blocking agents (NMBAs) are classified according to their interaction with nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction (NMJ). <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine</a>, the only depolarizing NMBA in use, produces skeletal muscle relaxation by binding directly with nAChRs to cause prolonged depolarization. Nondepolarizing NMBAs act as competitive antagonists (competing with acetylcholine [ACh] for the binding sites at the nAChRs), preventing the initiation of action potential. The type of neuromuscular block determines the response to peripheral nerve stimulation used for monitoring the effects of NMBAs. (See <a href=\"topic.htm?path=monitoring-neuromuscular-blockade\" class=\"medical medical_review\">&quot;Monitoring neuromuscular blockade&quot;</a>.)</p><p>The NMJ consists of the presynaptic motor neuron, a synaptic cleft or gap, and the postsynaptic surface of the myocyte (<a href=\"image.htm?imageKey=ANEST%2F114133\" class=\"graphic graphic_figure graphicRef114133 \">figure 5</a>) [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/14\" class=\"abstract_t\">14</a>]. As an electrical signal in a motor nerve reaches the presynaptic nerve terminal, depolarization occurs, and acetylcholine (ACh) is released via calcium channel-mediated exocytosis into the synaptic cleft. This cleft is home to acetylcholinesterase, the enzyme that breaks down ACh. Fifty percent of the released ACh is cleaved by acetylcholinesterase, and the remaining molecules bind to postsynaptic nicotinic ACh receptors (nAChRs) on the motor end plate, which causes ion channels to open. When enough channels are opened, the myocyte is depolarized and muscle contraction occurs. Acetylcholine remaining in the synapse is rapidly degraded by acetylcholinesterase, and the muscle is allowed to repolarize. </p><p class=\"headingAnchor\" id=\"H370576226\"><span class=\"h1\">SUCCINYLCHOLINE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine</a> (SCh) (also known as diacetylcholine or suxamethonium chloride) is the only depolarizing NMBA available for clinical use. </p><p class=\"headingAnchor\" id=\"H2517648691\"><span class=\"h2\">Pharmacology of succinylcholine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine</a> produces a reliable neuromuscular blockade that is the fastest in onset and shortest in duration of all NMBAs. Thus succinylcholine is often used for rapid sequence induction and intubation. (See <a href=\"topic.htm?path=rapid-sequence-induction-and-intubation-rsii-for-anesthesia#H107498340\" class=\"medical medical_review\">&quot;Rapid sequence induction and intubation (RSII) for anesthesia&quot;, section on 'Succinylcholine'</a> and <a href=\"#H2476711246\" class=\"local\">'Endotracheal intubation'</a> above.) </p><p>Within 30 seconds after intravenous administration, patients experience fasciculations from depolarization and antidromic activation of unparalyzed portions of the motor unit [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/87\" class=\"abstract_t\">87</a>]; flaccid paralysis ensues seconds later. Fasciculations of varying duration and intensity occur in 94 percent of patients [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/88\" class=\"abstract_t\">88</a>]. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong><span class=\"nowrap\">Dosing/onset</span> of action</strong> &ndash; An intravenous dose of 1 to 1.5 <span class=\"nowrap\">mg/kg,</span> or 3 to 5 x ED<sub>95</sub>,<sub> </sub>yields flaccid paralysis in one to two minutes. After an intubating dose, the clinical duration of action (defined as the time from drug administration until recovery of single twitch to 25 percent of baseline) is 7 to 12 minutes. If intravenous access is unavailable, <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a> can also be administered intramuscularly (3 to 4 <span class=\"nowrap\">mg/kg),</span> and paralysis will occur in approximately four minutes.</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine</a> is occasionally administered by infusion, titrated to twitch depression, most often when a brief period of neuromuscular blockade is required (such as electroconvulsive therapy). Use of a succinylcholine infusion or by repeated bolus administration increase the risk of Phase II block, and prolonged paralysis. Phase II block usually occurs after total succinylcholine doses exceeding 4 <span class=\"nowrap\">mg/kg</span>. Alternatives to succinylcholine infusion for short procedures include <a href=\"topic.htm?path=mivacurium-drug-information\" class=\"drug drug_general\">mivacurium</a>, or intermediate duration steroidal NMBAs (ie, <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a> or <a href=\"topic.htm?path=vecuronium-drug-information\" class=\"drug drug_general\">vecuronium</a>) followed by reversal with <a href=\"topic.htm?path=sugammadex-drug-information\" class=\"drug drug_general\">sugammadex</a>. (See <a href=\"#H3111531992\" class=\"local\">'Mivacurium'</a> below and <a href=\"#H3132576103\" class=\"local\">'Sugammadex'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pharmacokinetics</strong> &ndash; <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine</a> is metabolized by butyrylcholinesterase (also known as pseudocholinesterase or plasma cholinesterase) in a process that yields no active metabolites. </p><p/><p class=\"headingAnchor\" id=\"H1229187692\"><span class=\"h3\">Phase II block</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Phase II block typically develops after large doses of <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a> (&gt;4 <span class=\"nowrap\">mg/kg),</span> after repeated doses, or after a continuous infusion; some characteristics of phase II block have been described in doses as low as 0.3 <span class=\"nowrap\">mg/kg</span> [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/89\" class=\"abstract_t\">89</a>]. This type of block occurs when the post-junctional membrane action potential eventually returns to baseline, despite the continued activation of nAChRs in the presence of succinylcholine. Phase II block is associated with some of the features of nondepolarizing block, including train-of-four fade and post-tetanic potentiation.</p><p class=\"headingAnchor\" id=\"H2104230870\"><span class=\"h3\">Butyrylcholinesterase (pseudocholinesterase) deficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with atypical or deficient butyrylcholinesterase, recovery from <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a> (and <a href=\"topic.htm?path=mivacurium-drug-information\" class=\"drug drug_general\">mivacurium</a>) can be prolonged. A variety of factors can reduce butyrylcholinesterase activity but only modestly prolong paralysis with succinylcholine, including liver disease, pregnancy, advanced age, renal failure, major burns, oral contraceptives, and <a href=\"topic.htm?path=echothiophate-drug-information\" class=\"drug drug_general\">echothiophate</a> eye drops. In contrast, abnormal genetic variants of the butyrylcholinesterase enzyme can cause marked prolongation of paralysis after succinylcholine administration. Duration of paralysis may be increased by 50 to 100 percent in patients who are heterozygous for abnormal butyrylcholinesterase. Patients who are homozygous for the abnormal gene may be paralyzed for up to eight hours after an intubating dose of succinylcholine, and may require prolonged postoperative mechanical ventilation [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/90\" class=\"abstract_t\">90</a>]. </p><p>Atypical butyrylcholinesterase is often diagnosed after a patient has an unexpectedly prolonged response to <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a>. Objective train-of-four (TOF) monitoring should be used, and recovery documented prior to extubation, for all patients who have received NMBAs, including those who have received succinylcholine. Some degree of recovery from succinylcholine induced block should be documented prior to administration of a nondepolarizing NMBA, as administration of a nondepolarizing NMBA prior to documenting recovery from succinylcholine will complicate evaluation and subsequent management, should prolonged succinylcholine block occur. Principles for management of prolonged block after succinylcholine should include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Causes for prolonged block other than butyrylcholinesterase deficiency should be ruled out, including hypothermia and electrolyte disorders, or malfunctioning of the peripheral nerve stimulator or neuromuscular monitor </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>TOF fade is indicative of phase II block that is likely to occur in these patients. Reversal with <a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">neostigmine</a> should <strong>not</strong> be attempted. Anticholinesterase agents can worsen paralysis and induce phase II block in this setting. Lack of fade may indicate resolution of phase II block, but the degree of recovery from phase I block cannot be assessed without a baseline, pre-NMBA twitch.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The patient should be sedated and mechanically ventilated until full return of muscle strength as determined by quantitative monitoring if available. If quantitative monitoring is not available, the subjective monitoring with a peripheral nerve stimulator is warranted to confirm recovery. </p><p/><p>After an episode of prolonged paralysis after <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a>, testing may be performed for the level and activity of butyrylcholinesterase. Blood tests are usually sent to specialized laboratories, and should be drawn after the patient has recovered full muscle strength. Two tests are performed, one for the level of enzyme activity, and if enough activity exists, another for the <a href=\"topic.htm?path=dibucaine-drug-information\" class=\"drug drug_general\">dibucaine</a> number, which indicates the percent of inhibition of the enzyme under standardized test conditions. Dibucaine inhibition of 70 to 80 percent indicates a normal enzyme, whereas dibucaine inhibition of 20 to 30 percent indicates a homozygous atypical enzyme. These tests are not routinely performed in hospital laboratories, and blood samples are usually sent to specialized testing centers.</p><p class=\"headingAnchor\" id=\"H996697223\"><span class=\"h2\">Adverse effects of succinylcholine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine</a> is associated with a number of adverse effects, many of which are related to its depolarizing effect. Succinylcholine is contraindicated for patients with susceptibility to malignant hyperthermia, denervating conditions, major burns after 48 hours, and severe hyperkalemia.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hyperkalemia</strong> &ndash; Serum potassium levels increase by approximately 0.5 <span class=\"nowrap\">mEq/L</span> after the administration of 1 <span class=\"nowrap\">mg/kg</span> <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a>. This increase is exaggerated and may be life-threatening in patients who have upregulation of extra junctional nicotinic acetylcholine receptors (nAChRs), (eg, stroke with paralysis, spinal cord injury, muscle and muscle membrane disorders, muscular sclerosis, and polyneuropathies, sepsis, prolonged bed rest), or significant burns [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/91,92\" class=\"abstract_t\">91,92</a>]. The administration of a small dose of a nondepolarizing NMBA prior to succinylcholine (ie, a defasciculating dose) does not reliably prevent the rise in potassium associated with succinylcholine.</p><p/><p/><p class=\"bulletIndent1\">Administration of <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a> for routine intubation in children has largely been abandoned. The Food and Drug Administration of the United States has issued a boxed warning for succinylcholine for children, except for emergency airway management, over concerns for acute rhabdomyolysis and hyperkalemia in children with undiagnosed muscular dystrophies. Despite the warning, succinylcholine can be used in carefully screened children in select circumstances (eg, for rapid sequence induction and intubation [RSII]). (See <a href=\"topic.htm?path=general-anesthesia-in-neonates-and-children-agents-and-techniques#H4209807446\" class=\"medical medical_review\">&quot;General anesthesia in neonates and children: Agents and techniques&quot;, section on 'Intravenous induction medications'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Malignant hyperthermia</strong> &ndash; <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine</a> is a known trigger for malignant hyperthermia (MH), and its use is contraindicated in patients at risk for MH. (See <a href=\"topic.htm?path=susceptibility-to-malignant-hyperthermia-evaluation-and-management\" class=\"medical medical_review\">&quot;Susceptibility to malignant hyperthermia: Evaluation and management&quot;</a> and <a href=\"topic.htm?path=malignant-hyperthermia-clinical-diagnosis-and-management-of-acute-crisis\" class=\"medical medical_review\">&quot;Malignant hyperthermia: Clinical diagnosis and management of acute crisis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Myalgias</strong> &ndash; Nearly half of patients experience myalgias after receiving <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a>. Such myalgias were initially thought to be related to the fasciculations. However, the use of a nondepolarizing NMBA or &quot;defasciculating&quot; dose may attenuate, but does not reliably prevent, myalgias [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/14\" class=\"abstract_t\">14</a>]. Nonsteroidal anti-inflammatory drugs are the most effective means of attenuating succinylcholine-induced myalgias (number-needed-to-treat of 2.5 to 3), but only prevent myalgia in one-third of patients [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/88\" class=\"abstract_t\">88</a>].</p><p/><p class=\"bulletIndent1\">Pretreatment with nondepolarizing NMBAs can produce partial neuromuscular blockade, which results in visual disturbances, difficulty breathing, and other adverse effects [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/88\" class=\"abstract_t\">88</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Increased intragastric pressure</strong> &ndash; While <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a> increases intragastric pressure, the risk of aspiration is mitigated by a simultaneous increase in the lower esophageal sphincter tone.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Increased intraocular pressure</strong> &ndash; <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine</a> can cause increased intraocular pressure by up to 15 mmHg via unknown mechanisms. The optimal strategy for RSII in the setting of an open eye with a full stomach is debated, and must be individualized. (See <a href=\"topic.htm?path=anesthesia-for-emergent-eye-surgery#H199446603\" class=\"medical medical_review\">&quot;Anesthesia for emergent eye surgery&quot;, section on 'Induction of anesthesia'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Increased intracranial pressure</strong> &mdash; <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine</a> can produce a transient increase in intracranial pressure, which can be attenuated by administration of a defasciculating dose of nondepolarizing NMBA. (See <a href=\"topic.htm?path=anesthesia-for-craniotomy#H78577983\" class=\"medical medical_review\">&quot;Anesthesia for craniotomy&quot;, section on 'Neuromuscular blocking agents'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Cardiac dysrhythmias</strong> &mdash; <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine</a> may cause a variety of arrhythmias [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/93\" class=\"abstract_t\">93</a>]. Bradycardia is the most common of these, and occurs most frequently in children, or with repeated administration. Some clinicians routinely administer <a href=\"topic.htm?path=atropine-drug-information\" class=\"drug drug_general\">atropine</a> prior to RSII with succinylcholine in children to prevent bradycardia or asystole. (See <a href=\"topic.htm?path=general-anesthesia-in-neonates-and-children-agents-and-techniques#H3467450533\" class=\"medical medical_review\">&quot;General anesthesia in neonates and children: Agents and techniques&quot;, section on 'Rapid sequence induction and intubation'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Allergic reactions</strong> &ndash; NMBAs are among the commonly implicated triggers for perioperative anaphylaxis. The reported incidence of anaphylaxis varies, but it appears that the rates of anaphylaxis to <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a> and <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a> are significantly higher than the rates of reaction to other NMBAs [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/94\" class=\"abstract_t\">94</a>]. (See <a href=\"topic.htm?path=perioperative-anaphylaxis-clinical-manifestations-etiology-and-management#H315537455\" class=\"medical medical_review\">&quot;Perioperative anaphylaxis: Clinical manifestations, etiology, and management&quot;, section on 'Neuromuscular-blocking agents'</a>.) &#160; </p><p/><p class=\"headingAnchor\" id=\"H3507460328\"><span class=\"h1\">NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nondepolarizing, competitive, neuromuscular blocking agents (NMBAs) are classified by their chemical structure (steroidal versus benzylisoquinolinium) as well as their duration of action (short-, intermediate-, or long-acting agents). The properties of NMBAs are shown in tables (<a href=\"image.htm?imageKey=ANEST%2F114207\" class=\"graphic graphic_table graphicRef114207 \">table 4</a> and <a href=\"image.htm?imageKey=ANEST%2F114210\" class=\"graphic graphic_table graphicRef114210 \">table 3</a> and <a href=\"image.htm?imageKey=ANEST%2F114271\" class=\"graphic graphic_table graphicRef114271 \">table 5</a>). </p><p class=\"headingAnchor\" id=\"H1229812700\"><span class=\"h2\">Pharmacology of nondepolarizing neuromuscular blocking agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, the speed of onset of neuromuscular block depends on the potency of the drug; greater potency is associated with slower onset of block. Thus, <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a>, with an ED<sub>95</sub> of 0.3 <span class=\"nowrap\">mg/kg</span> IV, has a much more rapid onset than <a href=\"topic.htm?path=vecuronium-drug-information\" class=\"drug drug_general\">vecuronium</a>, which has an ED<sub>95</sub> of 0.05 <span class=\"nowrap\">mg/kg</span> (<a href=\"image.htm?imageKey=ANEST%2F114207\" class=\"graphic graphic_table graphicRef114207 \">table 4</a>). The standard intubating dose of nondepolarizing NMBAs is 2 to 3 times the ED<sub>95</sub> for the specific drug. Higher doses of some drugs speed onset of block and may be used for rapid sequence induction and intubation (RSII), though with a prolonged duration of block. </p><p>A dose of 10 percent of the ED<sub>95 </sub>may be utilized to maintain an existing level of neuromuscular block during anesthesia, guided by neuromuscular monitoring. (See <a href=\"#H1994682241\" class=\"local\">'Facilitation of surgery'</a> above.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Steroidal compounds &mdash; </strong><a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">Rocuronium</a> and <a href=\"topic.htm?path=vecuronium-drug-information\" class=\"drug drug_general\">vecuronium</a> are intermediate-acting, steroidal NMBAs. <a href=\"topic.htm?path=pancuronium-drug-information\" class=\"drug drug_general\">Pancuronium</a> and pipecuronium are the only available long-acting steroidal NMBAs. Pipecuronium is no longer commercially available in North America.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Benzylisoquinolinium compounds &mdash; </strong><a href=\"topic.htm?path=mivacurium-drug-information\" class=\"drug drug_general\">Mivacurium</a> is the only short-acting, benzylisoquinolinium NMBA. Mivacurium became commercially available in 2017 in the United States after a hiatus of approximately 10 years that was due to manufacturing issues. </p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=atracurium-drug-information\" class=\"drug drug_general\">Atracurium</a> and its isomer <a href=\"topic.htm?path=cisatracurium-drug-information\" class=\"drug drug_general\">cisatracurium</a> are two intermediate-acting benzylisoquinolinium NMBAs. Curare (d-Tubocurarine) is a long-acting benzylisoquinolinium NMBA that is not available in North America.</p><p/><p class=\"headingAnchor\" id=\"H3502991180\"><span class=\"h2\">Steroidal neuromuscular blocking agents</span></p><p class=\"headingAnchor\" id=\"H874124449\"><span class=\"h3\">Rocuronium</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">Rocuronium</a> has a faster onset than other nondepolarizing NMBAs. Thus rocuronium may be used at higher doses as an alternative to <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a> for RSII. (See <a href=\"topic.htm?path=induction-agents-for-rapid-sequence-intubation-in-adults-outside-the-operating-room\" class=\"medical medical_review\">&quot;Induction agents for rapid sequence intubation in adults outside the operating room&quot;</a>.) </p><p><a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">Rocuronium</a> does not release histamine, nor is it vagolytic, and it causes minimal hemodynamic effects. The incidence of allergic reactions to rocuronium and <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a> appears to be higher than other NMBAs. (See <a href=\"topic.htm?path=perioperative-anaphylaxis-clinical-manifestations-etiology-and-management#H315537455\" class=\"medical medical_review\">&quot;Perioperative anaphylaxis: Clinical manifestations, etiology, and management&quot;, section on 'Neuromuscular-blocking agents'</a>.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong><span class=\"nowrap\">Dosing/onset</span> of action &ndash;</strong> The standard intubating dose of 0.6 <span class=\"nowrap\">mg/kg</span> (2 x ED<sub>95</sub>) provides adequate intubating conditions in 1.5 to 3 minutes in most (but not all) patients. (See <a href=\"#H2476711246\" class=\"local\">'Endotracheal intubation'</a> above.)</p><p/><p class=\"bulletIndent1\">After an intubating dose, the clinical duration of action is 30 to 70 minutes. Thereafter, doses of 0.1 <span class=\"nowrap\">mg/kg</span> or an infusion at a dose of 5 to 12 <span class=\"nowrap\">mcg/kg/min</span> can be used to maintain neuromuscular blockade, guided by neuromuscular monitoring. The RSII dose of <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a> of 1.2 <span class=\"nowrap\">mg/kg,</span> or 4 x ED<sub>95</sub>,<sub> </sub>has a similar average onset time as <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a>, although the variability in onset is greater with rocuronium [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/95\" class=\"abstract_t\">95</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pharmacokinetics &ndash;</strong> <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">Rocuronium</a> has a volume of distribution of 0.3 to 0.7 <span class=\"nowrap\">L/kg</span>. It is excreted mostly through the biliary route, although a small portion is excreted renally. Its metabolism results in 17-desacetyl-rocuronium, a compound that has 20 percent the activity of the parent compound.</p><p/><p class=\"headingAnchor\" id=\"H3496358285\"><span class=\"h3\">Vecuronium</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vecuronium-drug-information\" class=\"drug drug_general\">Vecuronium</a> is a steroidal NMBA with minimal hemodynamic effects. It is not used as an alternative to <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a> for RSII because of slower onset time compared with <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a>. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><span class=\"nowrap\">Dosing/onset</span> of action &ndash; An intubating dose of <a href=\"topic.htm?path=vecuronium-drug-information\" class=\"drug drug_general\">vecuronium</a> of 0.1 <span class=\"nowrap\">mg/kg,</span> or 2 x ED<sub>95 </sub>provides adequate intubating conditions in three to four minutes. The maintenance dose is 0.01 <span class=\"nowrap\">mg/kg,</span> or an infusion at 1 to 2 <span class=\"nowrap\">mcg/kg/min,</span> guided by neuromuscular monitoring. Following an intubating dose, the clinical duration of action is 25 to 50 minutes.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pharmacokinetics &ndash; <a href=\"topic.htm?path=vecuronium-drug-information\" class=\"drug drug_general\">Vecuronium</a> has a volume of distribution of 0.4 <span class=\"nowrap\">L/kg</span>. It is excreted both through the biliary and renal routes. Thus patients with renal or hepatic disease may have a prolonged response to vecuronium, and maintenance doses should be carefully guided by neuromuscular monitoring. Vecuronium is metabolized to 3-desacetyl-vecuronium, a compound that has 60 percent the activity of the parent compound.</p><p/><p class=\"headingAnchor\" id=\"H744534214\"><span class=\"h3\">Pancuronium</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=pancuronium-drug-information\" class=\"drug drug_general\">Pancuronium</a> is a long-acting steroidal NMBA that is rarely used because of a high incidence of postoperative residual neuromuscular weakness. Pancuronium can cause tachycardia as a result of direct sympathomimetic stimulation and blockade of cardiac muscarinic receptors [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/96\" class=\"abstract_t\">96</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong><span class=\"nowrap\">Dosing/onset</span> of action &ndash;</strong> An intubating dose of <a href=\"topic.htm?path=pancuronium-drug-information\" class=\"drug drug_general\">pancuronium</a> of 0.1 <span class=\"nowrap\">mg/kg</span> (1.5 x ED<sub>95</sub>) provides adequate intubating conditions in three to five minutes. The maintenance dose is 0.02 <span class=\"nowrap\">mg/kg</span>. Following an intubating dose, the clinical duration of action is 60 to 120 minutes. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pharmacokinetics &ndash;</strong> <a href=\"topic.htm?path=pancuronium-drug-information\" class=\"drug drug_general\">Pancuronium</a> has a volume of distribution of 0.2 to 0.3 <span class=\"nowrap\">L/kg</span>. It is eliminated mostly through the renal route, with approximately 20 percent biliary excretion. Pancuronium is metabolized to 17-OH-pancuronium and 3-OH- pancuronium, with the latter possessing 50 percent the activity of the parent compound. Pancuronium should generally be avoided in patients with renal and hepatic impairment. If necessary, maintenance doses should be carefully guided by neuromuscular monitoring.</p><p/><p class=\"headingAnchor\" id=\"H830025861\"><span class=\"h2\">Benzylisoquinolinium neuromuscular blocking agents</span></p><p class=\"headingAnchor\" id=\"H3215606083\"><span class=\"h3\">Atracurium</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=atracurium-drug-information\" class=\"drug drug_general\">Atracurium</a> is an intermediate-acting benzylisoquinolinium NMBA that is a mixture of 10 isomers. &#160;</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong><span class=\"nowrap\">Dosing/onset</span> of action &ndash;</strong> An intubating dose of <a href=\"topic.htm?path=atracurium-drug-information\" class=\"drug drug_general\">atracurium</a> of 0.5 <span class=\"nowrap\">mg/kg,</span> or 2 x ED<sub>95</sub> provides adequate intubating conditions in three to five minutes. The maintenance dose of atracurium is 0.1 <span class=\"nowrap\">mg/kg,</span> or an infusion at 10 to 20 <span class=\"nowrap\">mcg/kg/min,</span> guided by neuromuscular monitoring. At doses higher than 0.5 <span class=\"nowrap\">mg/kg,</span> atracurium increases plasma histamine levels, causing skin flushing, hypotension, and tachycardia [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/97\" class=\"abstract_t\">97</a>]. Following an intubating dose, the clinical duration of atracurium is 30 to 45 minutes.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pharmacokinetics &ndash;</strong> <a href=\"topic.htm?path=atracurium-drug-information\" class=\"drug drug_general\">Atracurium</a> is metabolized through nonspecific plasma esterase-mediated hydrolysis and a nonenzymatic, pH- and temperature-dependent degradation called Hofmann elimination. Laudanosine is the final product of Hofmann elimination, a compound that was found to be epileptogenic in animal studies when administered in large doses [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/98\" class=\"abstract_t\">98</a>]. Epileptogenic side effects have not been demonstrated in humans, and this byproduct has no significance at clinically relevant doses [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/99\" class=\"abstract_t\">99</a>]. Metabolism is essentially independent of hepatic and renal function, and atracurium has no active metabolites. The volume of distribution of atracurium is 0.15 <span class=\"nowrap\">L/kg</span>.</p><p/><p class=\"headingAnchor\" id=\"H3242425126\"><span class=\"h3\">Cisatracurium</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cisatracurium-drug-information\" class=\"drug drug_general\">Cisatracurium</a> is the <em>cis</em>-isomer of <a href=\"topic.htm?path=atracurium-drug-information\" class=\"drug drug_general\">atracurium</a> and is four times more potent than atracurium. In contrast to atracurium, it does not cause histamine release.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong><span class=\"nowrap\">Dosing/onset</span> of action</strong> &ndash; The intubating dose of <a href=\"topic.htm?path=cisatracurium-drug-information\" class=\"drug drug_general\">cisatracurium</a> of 0.15 to 0.2 <span class=\"nowrap\">mg/kg,</span> or 3 x ED<sub>95</sub>, provides adequate intubating conditions in four to seven minutes. The maintenance dose of cisatracurium is 0.01 <span class=\"nowrap\">mg/kg</span> or an infusion at 1 to 3 <span class=\"nowrap\">mcg/kg/min,</span> guided by neuromuscular monitoring. Following an intubating dose of cisatracurium, the clinical duration of action is 35 to 50 minutes.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pharmacokinetics</strong> &ndash; <a href=\"topic.htm?path=cisatracurium-drug-information\" class=\"drug drug_general\">Cisatracurium</a> is also primarily metabolized through Hofmann elimination. Cisatracurium has no active metabolites, and its volume of distribution is 0.16 <span class=\"nowrap\">L/kg</span>.</p><p/><p class=\"headingAnchor\" id=\"H3111531992\"><span class=\"h3\">Mivacurium</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=mivacurium-drug-information\" class=\"drug drug_general\">Mivacurium</a> is a short-acting nondepolarizing benzylisoquinolinium NMBA that was developed as a nondepolarizing alternative to <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a>. Large doses are required for intubation because of this drug&rsquo;s high potency. Clinical utility has been limited by the histamine release associated with these high doses [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/97\" class=\"abstract_t\">97</a>]. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong><span class=\"nowrap\">Dosing/onset</span> of action &ndash;</strong> An intubating dose of <a href=\"topic.htm?path=mivacurium-drug-information\" class=\"drug drug_general\">mivacurium</a> of 0.2 <span class=\"nowrap\">mg/kg,</span> or 3 x ED<sub>95</sub>, provides adequate intubating conditions in three to four minutes. The maintenance dose of mivacurium is 0.1 <span class=\"nowrap\">mg/kg</span> [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/100\" class=\"abstract_t\">100</a>], or an infusion at 5 to 8 <span class=\"nowrap\">mcg/kg/min,</span> guided by neuromuscular monitoring. Following an intubating dose of mivacurium, the clinical duration of action is 15 to 20 minutes.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pharmacokinetics &ndash;</strong> <a href=\"topic.htm?path=mivacurium-drug-information\" class=\"drug drug_general\">Mivacurium</a> is mostly metabolized by butyrylcholinesterase and should not be used in patients with butyrylcholinesterase deficiency, as such patients will have unpredictable and prolonged response. Mivacurium has a volume of distribution of 0.2 <span class=\"nowrap\">L/kg</span>. It does not have active metabolites. </p><p/><p class=\"bulletIndent1\">Reversal (antagonism) of <a href=\"topic.htm?path=mivacurium-drug-information\" class=\"drug drug_general\">mivacurium</a> with either <a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">neostigmine</a> or <a href=\"topic.htm?path=edrophonium-drug-information\" class=\"drug drug_general\">edrophonium</a> is faster than spontaneous recovery [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/101\" class=\"abstract_t\">101</a>], although neostigmine reversal of profound mivacurium block may result in prolongation of the block [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/102\" class=\"abstract_t\">102</a>]. </p><p/><p class=\"bulletIndent1\">Neuromuscular block that occurs after <a href=\"topic.htm?path=mivacurium-drug-information\" class=\"drug drug_general\">mivacurium</a> administration in patients with pseudocholinesterase deficiency is not completely reversed by <a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">neostigmine</a> [<a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/103\" class=\"abstract_t\">103</a>], and recovery from neuromuscular block in this setting should be confirmed by objective monitoring, with a train-of-four ratio (TOFR) &gt;0.9. &#160;</p><p/><p class=\"headingAnchor\" id=\"H4184684632\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neuromuscular blocking agents (NMBAs) are administered during anesthesia to facilitate endotracheal intubation <span class=\"nowrap\">and/or</span> to improve surgical conditions (<a href=\"image.htm?imageKey=ANEST%2F114082\" class=\"graphic graphic_table graphicRef114082 \">table 6</a>). Selection of NMBA is based on patient factors and the clinical indication. (See <a href=\"#H679390746\" class=\"local\">'Selection of neuromuscular blocking agents'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient factors can affect the response to NMBAs, including neuromuscular disease, burns, extremes of age, hepatic and renal dysfunction, and physiologic disturbances. Other medications (eg, inhaled anesthetics) can also affect the response to NMBAs. (See <a href=\"#H2359769701\" class=\"local\">'Factors that affect the response to neuromuscular blocking agents'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Deep neuromuscular block (ie, 0 to 1 twitch with neuromuscular monitoring) is used for endotracheal intubation, and for some surgical indications. We aim for a moderate level of neuromuscular block (ie, 2 to 3 twitches) for most surgical procedures. (See <a href=\"#H115343747\" class=\"local\">'Clinical use of neuromuscular blocking agents'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Full recovery of neuromuscular function (ie, train-of-four (TOF) ratio of &ge;0.9) must be achieved prior to extubation of the trachea. Residual neuromuscular block is associated with weakness of upper airway muscles, increased risk of aspiration, hypoxemia, awareness during emergence from anesthesia, and increased postoperative pulmonary complications. (See <a href=\"#H1726332908\" class=\"local\">'Avoidance of residual neuromuscular blockade'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A strategy for avoidance of residual neuromuscular blockade should include (see <a href=\"#H1726332908\" class=\"local\">'Avoidance of residual neuromuscular blockade'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Use intermediate or short acting NMBAs whenever possible</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Avoid deep neuromuscular block (ie, train-of-four count [TOFC] of zero) when clinically appropriate</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Use objective neuromuscular monitoring whenever possible to guide administration of NMBAs and assess recovery</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Administer reversal agents in appropriate doses, guided by the degree of recovery from neuromuscular block (See <a href=\"#H154268994\" class=\"local\">'Reversal of neuromuscular block'</a> above.)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Extubate the trachea only after a TOF ratio &ge;0.9 is achieved, as indicated by objective monitoring</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If a quantitative monitor is not available, during <a href=\"topic.htm?path=sevoflurane-drug-information\" class=\"drug drug_general\">sevoflurane</a> anesthesia, wait at least 15 minutes after administration of <a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">neostigmine</a> to extubate if neostigmine is administered at a TOFC of 3, and at least 10 minutes if administered at a TOFC of 4. During intravenous anesthesia with <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, wait at least five minutes to extubate after neostigmine administration if it is administered at a TOFC &ge;3.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reversal of neuromuscular blockade can occur by spontaneous recovery, or by administration of reversal agents (ie, <a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">neostigmine</a> or <a href=\"topic.htm?path=sugammadex-drug-information\" class=\"drug drug_general\">sugammadex</a>). The doses of neostigmine and sugammadex should be based on the level of existing neuromuscular block at the time of administration (<a href=\"image.htm?imageKey=ANEST%2F114082\" class=\"graphic graphic_table graphicRef114082 \">table 6</a> and <a href=\"image.htm?imageKey=ANEST%2F114148\" class=\"graphic graphic_figure graphicRef114148 \">figure 4</a>). (See <a href=\"#H154268994\" class=\"local\">'Reversal of neuromuscular block'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>NMBAs are classified according to their interaction with nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction. <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine</a> produces skeletal muscle relaxation by binding directly with nAChRs to cause prolonged depolarization. Nondepolarizing NMBAs act as competitive antagonists for acetylcholine at nAChRs to prevent the initiation of an action potential (<a href=\"image.htm?imageKey=ANEST%2F114271\" class=\"graphic graphic_table graphicRef114271 \">table 5</a>). (See <a href=\"#H3484879739\" class=\"local\">'Classification of neuromuscular blocking agents'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine</a> is most often used for endotracheal intubation. It causes muscle fasciculations, an increase in serum potassium, and may cause postoperative myalgias. Succinylcholine is contraindicated in patients with severe burns, denervating neuromuscular diseases and stroke, susceptibility to malignant hyperthermia, and butyrylcholinesterase deficiency. (See <a href=\"#H370576226\" class=\"local\">'Succinylcholine'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">Rocuronium</a> and <a href=\"topic.htm?path=vecuronium-drug-information\" class=\"drug drug_general\">vecuronium</a> are the commonly used intermediate duration aminosteroid nondepolarizing NMBAs. They are used for endotracheal intubation and to facilitate surgery. Vecuronium and rocuronium have minimal cardiovascular side effects. They should be avoided or used with careful monitoring in patients with renal or hepatic dysfunction. (See <a href=\"#H3502991180\" class=\"local\">'Steroidal neuromuscular blocking agents'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cisatracurium-drug-information\" class=\"drug drug_general\">Cisatracurium</a>, <a href=\"topic.htm?path=atracurium-drug-information\" class=\"drug drug_general\">atracurium</a>, and <a href=\"topic.htm?path=mivacurium-drug-information\" class=\"drug drug_general\">mivacurium</a> are benzylisoquinolinium nondepolarizing NMBAs. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=cisatracurium-drug-information\" class=\"drug drug_general\">Cisatracurium</a> and <a href=\"topic.htm?path=atracurium-drug-information\" class=\"drug drug_general\">atracurium</a> are intermediate duration of action NMBAs that are used for endotracheal intubation and for facilitation of surgery. They are metabolized through Hofmann elimination, and do not depend on renal or hepatic function. Atracurium, but not cisatracurium, releases histamine at higher doses and can cause hypotension. (See <a href=\"#H3215606083\" class=\"local\">'Atracurium'</a> above and <a href=\"#H3242425126\" class=\"local\">'Cisatracurium'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=mivacurium-drug-information\" class=\"drug drug_general\">Mivacurium</a> is a short acting NMBA that is metabolized by plasma butyrylcholinesterase, and should be avoided in patients with atypical or deficient butyrylcholinesterase. At high doses, mivacurium releases histamine. (See <a href=\"#H3111531992\" class=\"local\">'Mivacurium'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/1\" class=\"nounderline abstract_t\">CULLEN SC. Curare; its rational use as an adjunct to anesthesia. Surgery 1946; 20:200.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/2\" class=\"nounderline abstract_t\">Williams MT, Rice I, Ewen SP, Elliott SM. A comparison of the effect of two anaesthetic techniques on surgical conditions during gynaecological laparoscopy. Anaesthesia 2003; 58:574.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/3\" class=\"nounderline abstract_t\">King M, Sujirattanawimol N, Danielson DR, et al. Requirements for muscle relaxants during radical retropubic prostatectomy. Anesthesiology 2000; 93:1392.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/4\" class=\"nounderline abstract_t\">Lieutaud T, Billard V, Khalaf H, Debaene B. Muscle relaxation and increasing doses of propofol improve intubating conditions. Can J Anaesth 2003; 50:121.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/5\" class=\"nounderline abstract_t\">Mencke T, Echternach M, Kleinschmidt S, et al. Laryngeal morbidity and quality of tracheal intubation: a randomized controlled trial. Anesthesiology 2003; 98:1049.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/6\" class=\"nounderline abstract_t\">Lemmens HJ, Brodsky JB. The dose of succinylcholine in morbid obesity. Anesth Analg 2006; 102:438.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/7\" class=\"nounderline abstract_t\">Leykin Y, Pellis T, Lucca M, et al. The effects of cisatracurium on morbidly obese women. Anesth Analg 2004; 99:1090.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/8\" class=\"nounderline abstract_t\">Weinstein JA, Matteo RS, Ornstein E, et al. Pharmacodynamics of vecuronium and atracurium in the obese surgical patient. Anesth Analg 1988; 67:1149.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/9\" class=\"nounderline abstract_t\">Lemmens HJ, Brodsky JB. Anesthetic drugs and bariatric surgery. Expert Rev Neurother 2006; 6:1107.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/10\" class=\"nounderline abstract_t\">Thapa S, Brull SJ. Succinylcholine-induced hyperkalemia in patients with renal failure: an old question revisited. Anesth Analg 2000; 91:237.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/11\" class=\"nounderline abstract_t\">Caldwell JE, Heier T, Wright PM, et al. Temperature-dependent pharmacokinetics and pharmacodynamics of vecuronium. Anesthesiology 2000; 92:84.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/12\" class=\"nounderline abstract_t\">Leslie K, Sessler DI, Bjorksten AR, Moayeri A. Mild hypothermia alters propofol pharmacokinetics and increases the duration of action of atracurium. Anesth Analg 1995; 80:1007.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/13\" class=\"nounderline abstract_t\">Heier T, Caldwell JE, Sessler DI, Miller RD. Mild intraoperative hypothermia increases duration of action and spontaneous recovery of vecuronium blockade during nitrous oxide-isoflurane anesthesia in humans. Anesthesiology 1991; 74:815.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/14\" class=\"nounderline abstract_t\">Naguib M, Flood P, McArdle JJ, Brenner HR. Advances in neurobiology of the neuromuscular junction: implications for the anesthesiologist. Anesthesiology 2002; 96:202.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/15\" class=\"nounderline abstract_t\">KATZ B, MILEDI R. THE EFFECT OF CALCIUM ON ACETYLCHOLINE RELEASE FROM MOTOR NERVE TERMINALS. Proc R Soc Lond B Biol Sci 1965; 161:496.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/16\" class=\"nounderline abstract_t\">Waud BE, Waud DR. Interaction of calcium and potassium with neuromuscular blocking agents. Br J Anaesth 1980; 52:863.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/17\" class=\"nounderline abstract_t\">Hill GE, Wong KC, Shaw CL, Blatnick RA. Acute and chronic changes in intra- and extracellular potassium and responses to neuromuscular blocking agents. Anesth Analg 1978; 57:417.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/18\" class=\"nounderline abstract_t\">Yamauchi M, Takahashi H, Iwasaki H, Namiki A. Respiratory acidosis prolongs, while alkalosis shortens, the duration and recovery time of vecuronium in humans. J Clin Anesth 2002; 14:98.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/19\" class=\"nounderline abstract_t\">Szalados JE, Donati F, Bevan DR. Effect of d-tubocurarine pretreatment on succinylcholine twitch augmentation and neuromuscular blockade. Anesth Analg 1990; 71:55.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/20\" class=\"nounderline abstract_t\">Naguib M, Abdulatif M, Selim M, al-Ghamdi A. Dose-response studies of the interaction between mivacurium and suxamethonium. Br J Anaesth 1995; 74:26.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/21\" class=\"nounderline abstract_t\">Cooper R, Mirakhur RK, Clarke RS, Boules Z. Comparison of intubating conditions after administration of Org 9246 (rocuronium) and suxamethonium. Br J Anaesth 1992; 69:269.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/22\" class=\"nounderline abstract_t\">Soppitt AJ, Glass PS, el-Moalem H, et al. Duration and recovery profile of cisatracurium after succinylcholine during propofol or isoflurane anesthesia. J Clin Anesth 1999; 11:652.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/23\" class=\"nounderline abstract_t\">Naguib M, Samarkandi AH, Bakhamees HS, et al. Comparative potency of steroidal neuromuscular blocking drugs and isobolographic analysis of the interaction between rocuronium and other aminosteroids. Br J Anaesth 1995; 75:37.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/24\" class=\"nounderline abstract_t\">Naguib M, Samarkandi AH, Ammar A, et al. Comparative clinical pharmacology of rocuronium, cisatracurium, and their combination. Anesthesiology 1998; 89:1116.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/25\" class=\"nounderline abstract_t\">Saitoh Y, Toyooka H, Amaha K. Recoveries of post-tetanic twitch and train-of-four responses after administration of vecuronium with different inhalation anaesthetics and neuroleptanaesthesia. Br J Anaesth 1993; 70:402.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/26\" class=\"nounderline abstract_t\">Rupp SM, Miller RD, Gencarelli PJ. Vecuronium-induced neuromuscular blockade during enflurane, isoflurane, and halothane anesthesia in humans. Anesthesiology 1984; 60:102.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/27\" class=\"nounderline abstract_t\">Gencarelli PJ, Miller RD, Eger EI 2nd, Newfield P. Decreasing enflurane concentrations and d-tubocurarine neuromuscular blockade. Anesthesiology 1982; 56:192.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/28\" class=\"nounderline abstract_t\">Wulf H, Ledowski T, Linstedt U, et al. Neuromuscular blocking effects of rocuronium during desflurane, isoflurane, and sevoflurane anaesthesia. Can J Anaesth 1998; 45:526.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/29\" class=\"nounderline abstract_t\">Burkett L, Bikhazi GB, Thomas KC Jr, et al. Mutual potentiation of the neuromuscular effects of antibiotics and relaxants. Anesth Analg 1979; 58:107.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/30\" class=\"nounderline abstract_t\">Ornstein E, Matteo RS, Schwartz AE, et al. The effect of phenytoin on the magnitude and duration of neuromuscular block following atracurium or vecuronium. Anesthesiology 1987; 67:191.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/31\" class=\"nounderline abstract_t\">Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 1986; 27:490.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/32\" class=\"nounderline abstract_t\">Martin BA, Kramer PM. Clinical significance of the interaction between lithium and a neuromuscular blocker. Am J Psychiatry 1982; 139:1326.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/33\" class=\"nounderline abstract_t\">M&uuml;ller TC, Rocha JB, Morsch VM, et al. Antidepressants inhibit human acetylcholinesterase and butyrylcholinesterase activity. Biochim Biophys Acta 2002; 1587:92.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/34\" class=\"nounderline abstract_t\">Zencirci B. Sertraline-induced pseudocholinesterase enzyme deficiency. Int J Gen Med 2010; 3:375.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/35\" class=\"nounderline abstract_t\">Usubiaga JE, Standaert F. The effects of local anesthetics on motor nerve terminals. J Pharmacol Exp Ther 1968; 159:353.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/36\" class=\"nounderline abstract_t\">Matsuo S, Rao DB, Chaudry I, Foldes FF. Interaction of muscle relaxants and local anesthetics at the neuromuscular junction. Anesth Analg 1978; 57:580.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/37\" class=\"nounderline abstract_t\">Sahin SH, Colak A, Sezer A, et al. Effect of epidural levobupivacaine on recovery from vecuronium-induced neuromuscular block in patients undergoing lower abdominal surgery. Anaesth Intensive Care 2011; 39:607.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/38\" class=\"nounderline abstract_t\">Suzuki T, Mizutani H, Ishikawa K, et al. Epidurally administered mepivacaine delays recovery of train-of-four ratio from vecuronium-induced neuromuscular block. Br J Anaesth 2007; 99:721.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/39\" class=\"nounderline abstract_t\">Munakata K, Suzuki T, Watanabe N, et al. [Influence of epidural lidocaine injection on vecuronium-induced neuromuscular blockade]. Masui 2004; 53:1377.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/40\" class=\"nounderline abstract_t\">Vivancos GG, Klamt JG, Garcia LV. Effects of 2 mg.kg&#8315;&sup1; of intravenous lidocaine on the latency of two different doses of rocuronium and on the hemodynamic response to orotracheal intubation. Rev Bras Anestesiol 2011; 61:1.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/41\" class=\"nounderline abstract_t\">Cardoso LS, Martins CR, Tardelli MA. Effects of intravenous lidocaine on the pharmacodynamics of rocuronium. Rev Bras Anestesiol 2005; 55:371.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/42\" class=\"nounderline abstract_t\">Czarnetzki C, Lysakowski C, Elia N, Tram&egrave;r MR. Intravenous lidocaine has no impact on rocuronium-induced neuromuscular block. Randomised study. Acta Anaesthesiol Scand 2012; 56:474.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/43\" class=\"nounderline abstract_t\">Heggeri VM, Harbishettar AS, Deka A, Rajkhowa T. Intubating Conditions of two Different Doses of Rocuronium At 60 Seconds; by Clinical Assessment; and with T.O.F Response of Adductor Pollicis Muscle. J Clin Diagn Res 2015; 9:UC24.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/44\" class=\"nounderline abstract_t\">Kopman AF, Klewicka MM, Neuman GG. Reexamined: the recommended endotracheal intubating dose for nondepolarizing neuromuscular blockers of rapid onset. Anesth Analg 2001; 93:954.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/45\" class=\"nounderline abstract_t\">Combes X, Andriamifidy L, Dufresne E, et al. Comparison of two induction regimens using or not using muscle relaxant: impact on postoperative upper airway discomfort. Br J Anaesth 2007; 99:276.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/46\" class=\"nounderline abstract_t\">Lundstr&oslash;m LH, Duez CH, N&oslash;rskov AK, et al. Avoidance versus use of neuromuscular blocking agents for improving conditions during tracheal intubation or direct laryngoscopy in adults and adolescents. Cochrane Database Syst Rev 2017; 5:CD009237.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/47\" class=\"nounderline abstract_t\">Hemmerling TM, Schmidt J, Hanusa C, et al. Simultaneous determination of neuromuscular block at the larynx, diaphragm, adductor pollicis, orbicularis oculi and corrugator supercilii muscles. Br J Anaesth 2000; 85:856.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/48\" class=\"nounderline abstract_t\">Mehta MP, Choi WW, Gergis SD, et al. Facilitation of rapid endotracheal intubations with divided doses of nondepolarizing neuromuscular blocking drugs. Anesthesiology 1985; 62:392.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/49\" class=\"nounderline abstract_t\">Engbaek J, Howardy-Hansen P, Ording H, Viby-Mogensen J. Precurarization with vecuronium and pancuronium in awake, healthy volunteers: the influence on neuromuscular transmission and pulmonary function. Acta Anaesthesiol Scand 1985; 29:117.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/50\" class=\"nounderline abstract_t\">Gueret G, Rossignol B, Kiss G, et al. Is muscle relaxant necessary for cardiac surgery? Anesth Analg 2004; 99:1330.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/51\" class=\"nounderline abstract_t\">Li YL, Liu YL, Xu CM, et al. The effects of neuromuscular blockade on operating conditions during general anesthesia for spinal surgery. J Neurosurg Anesthesiol 2014; 26:45.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/52\" class=\"nounderline abstract_t\">Blobner M, Frick CG, St&auml;uble RB, et al. Neuromuscular blockade improves surgical conditions (NISCO). Surg Endosc 2015; 29:627.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/53\" class=\"nounderline abstract_t\">Matsuzaki S, Jardon K, Maleysson E, et al. Impact of intraperitoneal pressure of a CO2 pneumoperitoneum on the surgical peritoneal environment. Hum Reprod 2012; 27:1613.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/54\" class=\"nounderline abstract_t\">Casanova J, Pi&ntilde;eiro P, De La Gala F, et al. [Deep versus moderate neuromuscular block during one-lung ventilation in lung resection surgery]. Rev Bras Anestesiol 2017; 67:288.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/55\" class=\"nounderline abstract_t\">Kopman AF, Naguib M. Laparoscopic surgery and muscle relaxants: is deep block helpful? Anesth Analg 2015; 120:51.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/56\" class=\"nounderline abstract_t\">Baete S, Vercruysse G, Vander Laenen M, et al. The Effect of Deep Versus Moderate Neuromuscular Block on Surgical Conditions and Postoperative Respiratory Function in Bariatric Laparoscopic Surgery: A Randomized, Double Blind Clinical Trial. Anesth Analg 2017; 124:1469.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/57\" class=\"nounderline abstract_t\">Barrio J, Errando CL, Garc&iacute;a-Ram&oacute;n J, et al. Influence of depth of neuromuscular blockade on surgical conditions during low-pressure pneumoperitoneum laparoscopic cholecystectomy: A randomized blinded study. J Clin Anesth 2017; 42:26.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/58\" class=\"nounderline abstract_t\">Cammu G, Boussemaere V, Foubert L, et al. Large bolus dose vs. continuous infusion of cisatracurium during hypothermic cardiopulmonary bypass surgery. Eur J Anaesthesiol 2005; 22:25.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/59\" class=\"nounderline abstract_t\">Berg H, Roed J, Viby-Mogensen J, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997; 41:1095.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/60\" class=\"nounderline abstract_t\">Murphy GS. Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period. Minerva Anestesiol 2006; 72:97.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/61\" class=\"nounderline abstract_t\">Murphy GS, Szokol JW, Marymont JH, et al. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg 2008; 107:130.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/62\" class=\"nounderline abstract_t\">Naguib M, Kopman AF, Ensor JE. Neuromuscular monitoring and postoperative residual curarisation: a meta-analysis. Br J Anaesth 2007; 98:302.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/63\" class=\"nounderline abstract_t\">Eriksson LI, Sundman E, Olsson R, et al. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans: simultaneous videomanometry and mechanomyography of awake human volunteers. Anesthesiology 1997; 87:1035.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/64\" class=\"nounderline abstract_t\">Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology 2003; 98:1042.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/65\" class=\"nounderline abstract_t\">Cronnelly R, Morris RB, Miller RD. Edrophonium: duration of action and atropine requirement in humans during halothane anesthesia. Anesthesiology 1982; 57:261.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/66\" class=\"nounderline abstract_t\">Bevan JC, Collins L, Fowler C, et al. Early and late reversal of rocuronium and vecuronium with neostigmine in adults and children. Anesth Analg 1999; 89:333.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/67\" class=\"nounderline abstract_t\">Kim KS, Cheong MA, Lee HJ, Lee JM. Tactile assessment for the reversibility of rocuronium-induced neuromuscular blockade during propofol or sevoflurane anesthesia. Anesth Analg 2004; 99:1080.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/68\" class=\"nounderline abstract_t\">Tajaate N, Schreiber JU, Fuchs-Buder T, et al. Neostigmine-based reversal of intermediate acting neuromuscular blocking agents to prevent postoperative residual paralysis: A systematic review. Eur J Anaesthesiol 2018; 35:184.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/69\" class=\"nounderline abstract_t\">Fuchs-Buder T, Meistelman C, Alla F, et al. Antagonism of low degrees of atracurium-induced neuromuscular blockade: dose-effect relationship for neostigmine. Anesthesiology 2010; 112:34.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/70\" class=\"nounderline abstract_t\">Goldhill DR, Wainwright AP, Stuart CS, Flynn PJ. Neostigmine after spontaneous recovery from neuromuscular blockade. Effect on depth of blockade monitored with train-of-four and tetanic stimuli. Anaesthesia 1989; 44:293.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/71\" class=\"nounderline abstract_t\">Payne JP, Hughes R, Al Azawi S. Neuromuscular blockade by neostigmine in anaesthetized man. Br J Anaesth 1980; 52:69.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/72\" class=\"nounderline abstract_t\">Caldwell JE. Reversal of residual neuromuscular block with neostigmine at one to four hours after a single intubating dose of vecuronium. Anesth Analg 1995; 80:1168.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/73\" class=\"nounderline abstract_t\">Murphy GS, Szokol JW, Avram MJ, et al. Neostigmine Administration after Spontaneous Recovery to a Train-of-Four Ratio of 0.9 to 1.0: A Randomized Controlled Trial of the Effect on Neuromuscular and Clinical Recovery. Anesthesiology 2018; 128:27.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/74\" class=\"nounderline abstract_t\">Bom A, Hope F, Rutherford S, Thomson K. Preclinical pharmacology of sugammadex. J Crit Care 2009; 24:29.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/75\" class=\"nounderline abstract_t\">Amorim P, Lagarto F, Gomes B, et al. Neostigmine vs. sugammadex: observational cohort study comparing the quality of recovery using the Postoperative Quality Recovery Scale. Acta Anaesthesiol Scand 2014; 58:1101.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/76\" class=\"nounderline abstract_t\">Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev 2017; 8:CD012763.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/77\" class=\"nounderline abstract_t\">White PF, Tufanogullari B, Sacan O, et al. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex. Anesth Analg 2009; 108:846.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/78\" class=\"nounderline abstract_t\">Shields M, Giovannelli M, Mirakhur RK, et al. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006; 96:36.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/79\" class=\"nounderline abstract_t\">S&oslash;rensen MK, Bretlau C, G&auml;tke MR, et al. Rapid sequence induction and intubation with rocuronium-sugammadex compared with succinylcholine: a randomized trial. Br J Anaesth 2012; 108:682.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/80\" class=\"nounderline abstract_t\">Cammu G, De Kam PJ, Demeyer I, et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaesth 2008; 100:373.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/81\" class=\"nounderline abstract_t\">Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103:695.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/82\" class=\"nounderline abstract_t\">Cammu G, Van Vlem B, van den Heuvel M, et al. Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment. Br J Anaesth 2012; 109:382.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/83\" class=\"nounderline abstract_t\">Zwiers A, van den Heuvel M, Smeets J, Rutherford S. Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modelling approach. Clin Drug Investig 2011; 31:101.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/84\" class=\"nounderline abstract_t\">Iwasaki H, Sasakawa T, Takahoko K, et al. A case series of re-establishment of neuromuscular block with rocuronium after sugammadex reversal. J Anesth 2016; 30:534.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/85\" class=\"nounderline abstract_t\">Tsur A, Kalansky A. Hypersensitivity associated with sugammadex administration: a systematic review. Anaesthesia 2014; 69:1251.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/86\" class=\"nounderline abstract_t\">Rahe-Meyer N, Fennema H, Schulman S, et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology 2014; 121:969.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/87\" class=\"nounderline abstract_t\">Meadows JC. Fasciculation caused by suxamethonium and other cholinergic agents. Acta Neurol Scand 1971; 47:381.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/88\" class=\"nounderline abstract_t\">Schreiber JU, Lysakowski C, Fuchs-Buder T, Tram&egrave;r MR. Prevention of succinylcholine-induced fasciculation and myalgia: a meta-analysis of randomized trials. Anesthesiology 2005; 103:877.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/89\" class=\"nounderline abstract_t\">Naguib M, Lien CA, Aker J, Eliazo R. Posttetanic potentiation and fade in the response to tetanic and train-of-four stimulation during succinylcholine-induced block. Anesth Analg 2004; 98:1686.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/90\" class=\"nounderline abstract_t\">Davis L, Britten JJ, Morgan M. Cholinesterase. Its significance in anaesthetic practice. Anaesthesia 1997; 52:244.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/91\" class=\"nounderline abstract_t\">Raman SK, San WM. Fasciculations, myalgia and biochemical changes following succinylcholine with atracurium and lidocaine pretreatment. Can J Anaesth 1997; 44:498.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/92\" class=\"nounderline abstract_t\">Mace SE. Challenges and advances in intubation: rapid sequence intubation. Emerg Med Clin North Am 2008; 26:1043.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/93\" class=\"nounderline abstract_t\">Yasuda I, Hirano T, Amaha K, et al. Chronotropic effects of succinylcholine and succinylmonocholine on the sinoatrial node. Anesthesiology 1982; 57:289.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/94\" class=\"nounderline abstract_t\">Reddy JI, Cooke PJ, van Schalkwyk JM, et al. Anaphylaxis is more common with rocuronium and succinylcholine than with atracurium. Anesthesiology 2015; 122:39.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/95\" class=\"nounderline abstract_t\">Tran DT, Newton EK, Mount VA, et al. Rocuronium versus succinylcholine for rapid sequence induction intubation. Cochrane Database Syst Rev 2015; :CD002788.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/96\" class=\"nounderline abstract_t\">Parmentier P, Dagnelie P. Dose-related tachycardia induced by pancuronium during balanced anaesthesia with and without droperidol. Br J Anaesth 1979; 51:157.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/97\" class=\"nounderline abstract_t\">Naguib M, Samarkandi AH, Bakhamees HS, et al. Histamine-release haemodynamic changes produced by rocuronium, vecuronium, mivacurium, atracurium and tubocurarine. Br J Anaesth 1995; 75:588.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/98\" class=\"nounderline abstract_t\">Chapple DJ, Miller AA, Ward JB, Wheatley PL. Cardiovascular and neurological effects of laudanosine. Studies in mice and rats, and in conscious and anaesthetized dogs. Br J Anaesth 1987; 59:218.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/99\" class=\"nounderline abstract_t\">Szakmany T, Woodhouse T. Use of cisatracurium in critical care: a review of the literature. Minerva Anestesiol 2015; 81:450.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/100\" class=\"nounderline abstract_t\">Dieck T, Steffens J, Sander B, et al. Propofol, remifentanil and mivacurium: fast track surgery with poor intubating conditions. Minerva Anestesiol 2011; 77:585.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/101\" class=\"nounderline abstract_t\">Maddineni VR, Mirakhur RK, McCoy EP. Recovery of mivacurium block with or without anticholinesterases following administration by continuous infusion. Anaesthesia 1994; 49:946.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/102\" class=\"nounderline abstract_t\">Kao YJ, Le ND. The reversal of profound mivacurium-induced neuromuscular blockade. Can J Anaesth 1996; 43:1128.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking-agents-in-anesthesia/abstract/103\" class=\"nounderline abstract_t\">Yang HS, Goudsouzian N, Martyn JA. Pseudocholinesterase-mediated hydrolysis is superior to neostigmine for reversal of mivacurium-induced paralysis in vitro. Anesthesiology 1996; 84:936.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 94535 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H4184684632\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H3496590383\" id=\"outline-link-H3496590383\">INTRODUCTION</a></li><li><a href=\"#H679390746\" id=\"outline-link-H679390746\">SELECTION OF NEUROMUSCULAR BLOCKING AGENTS</a></li><li><a href=\"#H2359769701\" id=\"outline-link-H2359769701\">FACTORS THAT AFFECT THE RESPONSE TO NEUROMUSCULAR BLOCKING AGENTS</a><ul><li><a href=\"#H1330254603\" id=\"outline-link-H1330254603\">Patient factors</a></li><li><a href=\"#H2313054767\" id=\"outline-link-H2313054767\">Drug interactions</a></li></ul></li><li><a href=\"#H115343747\" id=\"outline-link-H115343747\">CLINICAL USE OF NEUROMUSCULAR BLOCKING AGENTS</a><ul><li><a href=\"#H2476711246\" id=\"outline-link-H2476711246\">Endotracheal intubation</a></li><li><a href=\"#H1994682241\" id=\"outline-link-H1994682241\">Facilitation of surgery</a></li></ul></li><li><a href=\"#H1726332908\" id=\"outline-link-H1726332908\">AVOIDANCE OF RESIDUAL NEUROMUSCULAR BLOCKADE</a></li><li><a href=\"#H154268994\" id=\"outline-link-H154268994\">REVERSAL OF NEUROMUSCULAR BLOCK</a><ul><li><a href=\"#H3662862510\" id=\"outline-link-H3662862510\">Spontaneous recovery</a></li><li><a href=\"#H1667432385\" id=\"outline-link-H1667432385\">Anticholinesterases</a></li><li><a href=\"#H3132576103\" id=\"outline-link-H3132576103\">Sugammadex</a></li></ul></li><li><a href=\"#H3484879739\" id=\"outline-link-H3484879739\">CLASSIFICATION OF NEUROMUSCULAR BLOCKING AGENTS</a></li><li><a href=\"#H370576226\" id=\"outline-link-H370576226\">SUCCINYLCHOLINE</a><ul><li><a href=\"#H2517648691\" id=\"outline-link-H2517648691\">Pharmacology of succinylcholine</a><ul><li><a href=\"#H1229187692\" id=\"outline-link-H1229187692\">- Phase II block</a></li><li><a href=\"#H2104230870\" id=\"outline-link-H2104230870\">- Butyrylcholinesterase (pseudocholinesterase) deficiency</a></li></ul></li><li><a href=\"#H996697223\" id=\"outline-link-H996697223\">Adverse effects of succinylcholine</a></li></ul></li><li><a href=\"#H3507460328\" id=\"outline-link-H3507460328\">NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS</a><ul><li><a href=\"#H1229812700\" id=\"outline-link-H1229812700\">Pharmacology of nondepolarizing neuromuscular blocking agents</a></li><li><a href=\"#H3502991180\" id=\"outline-link-H3502991180\">Steroidal neuromuscular blocking agents</a><ul><li><a href=\"#H874124449\" id=\"outline-link-H874124449\">- Rocuronium</a></li><li><a href=\"#H3496358285\" id=\"outline-link-H3496358285\">- Vecuronium</a></li><li><a href=\"#H744534214\" id=\"outline-link-H744534214\">- Pancuronium</a></li></ul></li><li><a href=\"#H830025861\" id=\"outline-link-H830025861\">Benzylisoquinolinium neuromuscular blocking agents</a><ul><li><a href=\"#H3215606083\" id=\"outline-link-H3215606083\">- Atracurium</a></li><li><a href=\"#H3242425126\" id=\"outline-link-H3242425126\">- Cisatracurium</a></li><li><a href=\"#H3111531992\" id=\"outline-link-H3111531992\">- Mivacurium</a></li></ul></li></ul></li><li><a href=\"#H4184684632\" id=\"outline-link-H4184684632\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ANEST/94535|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ANEST/114139\" class=\"graphic graphic_figure\">- Muscle response during partial (moderate) neuromuscular block</a></li><li><a href=\"image.htm?imageKey=ANEST/114145\" class=\"graphic graphic_figure\">- Subjective eval neuromuscular responses at adductor pollicis</a></li><li><a href=\"image.htm?imageKey=ANEST/114147\" class=\"graphic graphic_figure\">- Placement of stimulating electrodes for monitoring of eye</a></li><li><a href=\"image.htm?imageKey=ANEST/114148\" class=\"graphic graphic_figure\">- Rocuronium recovery chart</a></li><li><a href=\"image.htm?imageKey=ANEST/114133\" class=\"graphic graphic_figure\">- Neuromuscular junction</a></li></ul></li><li><div id=\"ANEST/94535|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ANEST/114209\" class=\"graphic graphic_table\">- Sensitivity to NMBAs neuromuscular disease</a></li><li><a href=\"image.htm?imageKey=SURG/65645\" class=\"graphic graphic_table\">- Conditions associated with malignant hyperthermia</a></li><li><a href=\"image.htm?imageKey=ANEST/114210\" class=\"graphic graphic_table\">- Pharmacokin propert benzylisoquinolinium nondepolarizing NMBAs</a></li><li><a href=\"image.htm?imageKey=ANEST/114207\" class=\"graphic graphic_table\">- Pharmacokinetic properties aminosteroid nondepolarizing NMBAs</a></li><li><a href=\"image.htm?imageKey=ANEST/114271\" class=\"graphic graphic_table\">- Properties of NMBAs</a></li><li><a href=\"image.htm?imageKey=ANEST/114082\" class=\"graphic graphic_table\">- Management neuromuscular blockade according to monitoring</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-burn-patients\" class=\"medical medical_review\">Anesthesia for burn patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-craniotomy\" class=\"medical medical_review\">Anesthesia for craniotomy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-emergent-eye-surgery\" class=\"medical medical_review\">Anesthesia for emergent eye surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-intracranial-neurovascular-procedures-in-adults\" class=\"medical medical_review\">Anesthesia for intracranial neurovascular procedures in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-the-patient-with-myasthenia-gravis\" class=\"medical medical_review\">Anesthesia for the patient with myasthenia gravis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-the-patient-with-preeclampsia\" class=\"medical medical_review\">Anesthesia for the patient with preeclampsia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-anesthesia-in-neonates-and-children-agents-and-techniques\" class=\"medical medical_review\">General anesthesia in neonates and children: Agents and techniques</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=induction-agents-for-rapid-sequence-intubation-in-adults-outside-the-operating-room\" class=\"medical medical_review\">Induction agents for rapid sequence intubation in adults outside the operating room</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=malignant-hyperthermia-clinical-diagnosis-and-management-of-acute-crisis\" class=\"medical medical_review\">Malignant hyperthermia: Clinical diagnosis and management of acute crisis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-the-difficult-airway-for-general-anesthesia-in-adults\" class=\"medical medical_review\">Management of the difficult airway for general anesthesia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=monitoring-neuromuscular-blockade\" class=\"medical medical_review\">Monitoring neuromuscular blockade</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=perioperative-anaphylaxis-clinical-manifestations-etiology-and-management\" class=\"medical medical_review\">Perioperative anaphylaxis: Clinical manifestations, etiology, and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rapid-sequence-induction-and-intubation-rsii-for-anesthesia\" class=\"medical medical_review\">Rapid sequence induction and intubation (RSII) for anesthesia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=susceptibility-to-malignant-hyperthermia-evaluation-and-management\" class=\"medical medical_review\">Susceptibility to malignant hyperthermia: Evaluation and management</a></li></ul></div></div>","javascript":null}